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1INTRODUCTION
Breast cancer is the most common non-skin cancer in women worldwide
with an estimated 1.68 million new cases. It accounts for 23% of all cancers in
women. As per the 2008 estimates, breast cancer incidence has increased by
more than 20%, while mortality has increased by 14%. Breast cancer is the most
common cause of cancer death among women accounting for 522,000 deaths in
2012 .1 In India, breast cancer is the most common cancer that has been reported
from urban cancer registries, and accounts for about 30% of all cancers in
females.2 A large majority of the cases present at a younger age and with
advanced disease.3
Breast cancer is a complex and heterogeneous disease comprising of a
various biological entities, that are classified based on specific morphological
appearances, immunohistochemical features and clinical behaviour. In recent
years, it has become evident that this diversity is the result of genetic alterations.4
The extensive analysis of gene expression profiles of breast cancers using DNA
microarrays has led to the classification of breast cancer into molecular subtypes
which have distinct clinical features, with markedly differing prognoses and
clinical outcomes.5
Based on the study of gene expression profiles, breast cancers are divided
into five molecular subtypes: Luminal A(ER+), Luminal B (ER+),basal-like,
normal breast-like and human epidermal growth factor 2
(HER2) overexpressing subtype.6,7 Within these five subtypes, basal like
2breast cancer is characterized by absence of expression of estrogen receptor
(ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2).
It is associated with aggressive histomorphology, poor prognosis and
unresponsiveness to the hormonal chemotherapy, shorter survival and BRCA1
association. Although triple negative breast cancer (TNBC) is universally used
as a surrogate marker, triple negative and basal like are not synonymous.8
Triple-negative breast cancer (TNBC) is defined by the lack of expression
of estrogen receptor (ER), progesterone receptor (PR) and human epidermal
growth factor 2 (Her2neu) expression and associated with aggressive clinical
course and poor prognosis. Two subtypes of triple-negative breast cancers have
been described: basal and nonbasal.5 Triple-negative breast cancer(TNBC)
accounts for 10-17% of all breast cancers with increased incidence in
premenopausal women.9
Basal type TNBC characteristically exhibits high histological grade, p53
mutation, in most instances expresses basal cytokeratin (CK5/6, CK14 and
CK17), epidermal growth factor receptor (EGFR) overexpression, is
significantly associated with Ki-67 labelling index, p53 expression, and BRCA1
expression, and show a shorter survival than nonbasal type. Gene expression
profiling is the gold standard for the identification of basal type TNBC. Since
GEP is costly, cumbersome to perform and requires fresh or frozen samples, it is
still not feasible to perform GEP in low resource settings. Hence Rakha et al.
suggested the use of immunohistochemical surrogates panel for the identification
of basal-like subtype of TNBC. The panel includes four markers – ER, her2,
3cytokeratin 5/6 and epidermal growth factor receptor EGFR which identifies
basal-like TNBC with 100% specificity and 76% sensitivity.10 This study is to
apply the immunohistochemical panel to identify basal-like triple negative breast
cancer in our setting.
4AIM
To study the clinical, histomorphological characteristics of triple negative
breast cancer and to identify basal-like triple negative cancer subtype using
immunohistochemical panel of markers including CK5/6 and EGFR.
OBJECTIVES
1. To assess the clinicopathologic features of triple negative breast cancers.
2. To study the detailed histomorphological appearances of triple negative
breast cancers using various parameters.
3. To apply an immunohistochemical markers panel using CK5/6 and EGFR
for the identification of basal subtypes of triple negative breast cancers.
4. To assess the correlation between the basal markers CK 5/6 and EGFR
expression and clinicopathologic parameters.
5REVIEW OF LITERATURE
HISTORY
The paleopathologic findings from ancient mummies have indicated the
existence of cancers in prehistoric times, proving the old saying that cancer is as
old as the human race. The earliest written description of breast cancer is found
in the Edwin Smith Papyrus which dates back to 3000 BC. Edwin Smith Papyrus
describes breast cancer as bulging tumour of the breast which correlates with the
present scientific descriptions of breast cancer. The Egyptians were the first who
attempted to treat cancers. Later, Hippocrates (460 –375 BC) from Greece
described that the growing tumours were caused by humoral imbalance and
named them as carcinos meaning a tumour from the Greek word crab.11
CARCINOMA OF BREAST
Breast cancer is the most common cancer among women worldwide12.The
increased use of mammography has resulted in an increase in the early detection
of breast cancers in the western countries. Although there is a reasonable
reduction in the breast cancer mortality in the developed countries due to the
early diagnosis and advances in the treatment, it is still on the rise in most of the
Asian countries.13
EPIDEMIOLOGY
Breast cancer is the most common malignant tumour and it is the leading cause
of cancer deaths across the world with more than one million cases occurring
annually.13 It is now regarded as the most common cancer both in developed and
6developing regions with 690,000 new cases estimated in each region of the
world. In India, among the cancers occurred in Chennai, breast cancer is the most
common cancer with an age-standardized incidence rate of 30.8 per 100000
population.14
CLINICAL PRESENTATION
A large number of breast cancer cases present symptomatically. Recently
because of the widely used screening methods including mammography, the
incidence of asymptomatic cases has come to a rise. The symptomatic women
present most commonly with breast lumps (60-70%), followed by pain (14-
18%), nipple abnormalities like retraction and discharge (7-9%). Family history
is seen in about 3-14% of the cases. The least common presenting symptom
being inflammation (1%). The breast tumours are most commonly found in
upper outer quadrant of the breast (40-50%), followed by central, upper inner,
lower outer to lower inner quadrant.15
All the symptomatic breast diseases should be assessed using triple
assessment that includes clinical examination, imaging studies( mammography,
ultrasound)  and tissue sampling ( fine needle aspiration cytology or core needle
biopsy).15
RISK FACTORS FOR BREAST CANCER
AGE
Breast cancer is extremely rare in young women aged below 25 years
excepting some familial cases. Although breast cancer is rare in young age group
7females, half of those affected are either ER negative or HER2/neu positive in
the Western population. About 77% of breast cancers occur in women over 50
years of age with average age at diagnosis being 64 years. The incidence rises
throughout the lifetime of a woman. 16
AGE AT MENARCHE AND MENOPAUSE
Early age at menarche has been consistently associated with an increased
risk of breast cancer17. The estimated decrease in risk per five year delay in
menarche is 22%18. Late menopause occurring after the age of 55 years doubles
the risk of breast cancer than those who attain menopause before the age of 45
years19.
AGE AT FIRST CHILDBIRTH AND PARITY
Childbearing at a younger age lowers the risk of breast cancer. First
childbirth at a younger age of <30 years and multiple pregnancies reduces the
risk of breast cancer. The relative risk of developing breast cancer is estimated to
increase by 3% for each year of delay. The risk of breast cancer is reduced by
7% with each full term delivery and overall multiparous women have a 30%
lower risk of developing breast cancers than nulliparous women.20
RACE AND ETHNICITY
The incidence of mortality due to breast malignancies is more in African –
American women who present at a more advanced stage at diagnosis when
compared to white women21. A large number of breast cancer cases are
diagnosed in black women younger than 40 years of age, and the breast tumours
8occurring in black women exhibit higher nuclear grade, frequently do not express
hormone receptors, and have sporadic mutations in p53 gene22.
BREAST FEEDING
Breast feeding has consistently been associated with reduction in the risk
of breast cancer. The longer duration a woman breastfeeds, the greater is the
protection against breast cancer, and the risk is reduced by 4% for every 12
months of breastfeeding. In addition, the risk of breast cancer in women who had
breastfed for more than two years was 33% lower than those who had never
breastfed23. On the other hand, the higher incidence of breast cancer in developed
countries has been attributed to the lack of breast feeding or short lifetime
duration of breast feeding in these countries19.
PROLONGED EXPOSURE TO EXOGENOUS ESTROGEN
According to recent studies, women undergoing hormone replacement
therapy with combined estrogen and progestin have an increased risk of
developing breast cancer16.
RADIATION THERAPY
Ionized radiation forms an established risk factor for breast cancer. The
risk of developing breast cancer was the highest in women who had increased
number of exposures and at a younger age24.
9PREVIOUS BREAST DISEASE
Women with history of benign breast diseases have increased risk of
developing breast cancer. Women who had proliferative disease without atypia
on biopsy specimens have a two-fold increase and proliferative disease with
atypia have a five-fold increase in risk of breast cancer development25.
GENETIC AND FAMILY HISTORY
Women who have two or more first-degree relatives affected at an early
age have four-fold increase in the risk of development of breast cancer. Several
studies have shown consistent link between risk of breast cancer development
and inherited mutations in many genes like BRCA1, BRCA2, p53, PTEN and
ATM. The breast cancer genes, BRCA1, located on the long arm of chromosome
17 and BRCA2, which is located on the long arm of chromosome 13, have been
identified and mutations in these genes are established risk factors of breast
cancer. Inherited mutations in p53 and PTEN genes are associated with familial
syndromes like Li-Fraumeni and Cowden syndrome, and are at high risk of
developing breast cancer26.
OBESITY
Overweight and obesity, as defined by the measurement of body mass
index (BMI), are associated with increased incidence of breast cancers. The risk
is greater in postmenopausal women than in premenopausal women27.
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DIET
Several epidemiological studies have suggested that an increased
consumption of dietary fat is associated with an increase in breast cancer risk28.
SMOKING AND ALCOHOL CONSUMPTION
A meta-analysis study has found that the risk is higher in women who
start smoking at younger age, before the age of 20 or before the birth of their first
child29. Alcohol intake is consistently associated with increased risk of breast
cancer and the risk is dose-dependent regardless of the type of alcohol
consumed30.
PHYSICAL ACTIVITY
Several studies have found a strong association between physical activity
and breast cancer, with about 15-20% reduction of risk of developing breast
cancer in the most active women, with the strongest association shown for post-
menopausal women31.
INVASIVE CARCINOMA OF BREAST
Microscopically, invasive carcinoma of breast is classified into various
special types depending on the particular pattern they exhibit. Approximately
75% of the carcinomas do not represent any special types and they are labelled as
invasive ductal carcinoma, not-otherwise-specified (NOS) type.13
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WHO CLASSIFICATION OF INVASIVE CARCINOMA OF BREAST
1. Invasive ductal carcinoma, not otherwise specified
a. Pleomorphic carcinoma
b. Carcinoma with melanotic features
c. Carcinoma with choriocarcinomatous features
d. Carcinoma with osteoclast like giant cells
2. Invasive lobular carcinoma
a. Classic lobular carcinoma
b. Solid lobular carcinoma
c. Alveolar lobular carcinoma
d. Pleomorphic lobular carcinoma
e. Tubulolobular lobular carcinoma
f. Mixed lobular carcinoma
3. Tubular carcinoma
4. Cribriform carcinoma
5. Carcinoma with medullary features
a. Medullary carcinoma
b. Atypical medullary carcinoma
c. Invasive carcinoma NST with medullary features
6. Metaplastic carcinoma of no special type
a. Low-grade adenosquamous carcinoma
b. Fibromatosis-like metaplastic carcinoma
c. Squamous cell carcinoma
12
d. Spindle cell carcinoma
e. Metaplastic carcinoma with mesenchymal differentiation
i. Chondroid differentiation
ii. Osseous differentiation
iii. Other types of mesenchymal differentiation
f. Mixed metaplastic carcinoma
g. Myoepithelial carcinoma
7. Mucinous carcinoma
8. Carcinoma  with signet-ring-cell differentiation
9. Carcinoma with neuroendocrine features
10. Carcinoma with apocrine differentiation
11. Invasive papillary carcinoma
12. Invasive micropapillary carcinoma
13. Adenoid cystic carcinoma
14. Mucoepidermoid carcinoma
15. Salivary gland/skin adnexal type tumours
16. Polymorphous carcinoma
17. Inflammatory carcinoma
18. Bilateral breast carcinoma and non-synchronous breast carcinoma
19. Exceptionally rare types and variants
Secretory carcinoma
Oncocytic carcinoma
Sebaceous carcinoma
13
Lipid-rich carcinoma
Glycogen-rich clear cell carcinoma
Acinic cell carcinoma 32
1. INVASIVE DUCTAL CARCINOMA, NOT OTHERWISE SPECIFIED
Invasive ductal carcinoma of NOS type is a heterogeneous group of
tumours that do not have characteristics that are specific to any special type of
carcinoma to be classified as special types such as tubular, mucinous, medullary
or lobular carcinoma. It is the most common type of infiltrating breast cancers
which constitute about 47-75% of the cases.33 It is considered to be the prototype
of all breast cancers.34
GROSS FEATURES:
Grossly, the tumour varies in size and shape and presents as an ill
circumscribed, firm to hard mass. When cut, it gives a gritty feel. The cut surface
is greyish- yellow with a stellate outline produced by the trabeculae radiating
into the surrounding fat through the parenchyma. In larger tumours, there may be
areas of necrosis, cystic degeneration and haemorrhage seen. The cut surface of
these tumours, sometimes show a few ‘chalky streaks’, which are due to the duct
elastosis rather than necrosis.
14
FIG. 1(A) - INVASIVE DUCTAL CARCINOMA- CUT SURFACE
SHOWING WHITISH IRREGULAR MASS WITH CHALKY
STREAKS.
MICROSCOPY:
Microscopically, the tumour cells grow in varying patterns such as diffuse
sheets, cords, nests, trabeculae and even as individual cells. Glandular
differentiation may be marked, focally present or totally absent. The tumour cells
are large, pleomorphic, sometimes with multinucleated tumour giant cells. They
show characteristic features of malignancy like prominent nuclei and nucleoli
with numerous mitotic figures. About 60% of the cases show areas of necrosis.
Focal areas of squamous, apocrine metaplasia or clear cell change may be
present. As in any other carcinomas, the amount of stroma varies from nil to
abundant. The stroma ranges from fibrotic to desmoplastic in appearance, with
15
desmoplastic stroma being found in most of the cases. Stromal elastosis and foci
of periductal and perivenous elastosis may also be present. Calcifications in the
form of both coarse or fine granules and rarely psammoma bodies are seen in
about 60% of the cases. The interphase between tumour and stroma, often shows
lymphoplasmacytic inflammatory infiltrate. Fisher et al., found angioinvasion,
perineural invasion and lymphatic invasion in 33%, 28% and 5% respectively.13
In up to 80% of cases, foci of in situ component may be present,
however, the relative proportion of invasive carcinoma and in situ component
may largely vary in individual cases.33
FIG. 1(B): PROTOTYPICAL INVASIVE DUCTAL CARCINOMA
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2. INFILTRATING LOBULAR CARCINOMA:
Infiltrating lobular carcinoma is the second most common type of breast
cancer constituting to about 5-15% of the cases.33
HISTOLOGIC VARIANTS:
CLASSIC FORM:
The malignant cells are small, less pleomorphic and are arranged singly,
in a linear single file pattern, narrow trabeculae within the stroma. It may also
show a ‘pagetoid’/ concentric growth pattern around the lobules exhibiting
lobular neoplasia in situ. Often, the stroma appears dense and fibrous with
periductal and perivenous elastosis.13
PLEOMORPHIC VARIANT:
The growth pattern of this variant is similar to that of classic form with
lack of cohesion. The tumour cells exhibit nuclei that are highly pleomorphic,
anaplastic and show high mitotic rate. It sometimes, shows apocrine
differentiation and signet ring morphology.13
SOLID VARIANT:
It accounts for about 10% of lobular carcinoma cases. The tumour cells
are similar to classic type, but are arranged in diffuse sheets rather than single
files with very less amount of intervening stroma.33
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ALVEOLAR VARIANT:
It is an uncommon variant of lobular carcinoma in which the tumour cells
with typical lobular features are arranged in globular clusters of 20 or more cells
in each cluster.33
TUBULOLOBULAR VARIANT:
In this variant, the overall infiltrative pattern of lobular carcinoma cells is
admixed with small tubules showing minute or undetectable lumen. Often, there
is presence of in situ component, which may be of ductal, lobular or mixed
type.13
HISTIOCYTOID CARCINOMA:
It is composed of tumour cells growing in a diffuse pattern with individual
cells showing abundant, granular and foamy cytoplasm. It is currently considered
a variant of invasive lobular carcinoma with apocrine differentiation.13
IHC:
About 80-95% of invasive lobular carcinomas are positive for ER and 65-
75% is positive for PR. 70-75% of the tumours are positive for both ER and PR.
About 85-90% of invasive lobular carcinoma cases show loss of E-cadherin
expression.35
3. TUBULAR CARCINOMA:
Tubular carcinoma is an uncommon histologic type of breast carcinoma.
It accounts for about 1-4% of all breast malignancies.32
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GROSS:
Macroscopically, tubular carcinoma is indistinguishable from the invasive
ductal carcinoma. It has poorly circumscribed margins and hard in consistency.
Characteristically, the size of the tumour is small ranging from 2mm to 1.5 cm.
Most tumours are less than 1 cm in size.
MICROSCOPY:
Microscopically, it is difficult to differentiate from benign conditions like
radial scar and microglandular adenosis due to the well differentiated appearance
of tubular glands, scarcity/absence of pleomorphism, necrosis and mitoses. The
tubules are arranged haphazardly in the stroma and are often angulated. The
stroma is often cellular and desmoplastic in nature. The tubules may show
intraluminal basophilic secretions, apocrine snouts in the apical cytoplasm. The
tumour may infiltrate into the adjacent adipose tissue, at the periphery.
The term ‘tubular carcinoma’ is best reserved for the tumours showing at
least 90% of tubular pattern.36 These tumours show a favourable prognosis.
DCIS is frequently present in association with tubular carcinoma. The in situ
component is usually of low grade showing cribriform or papillary pattern.37 The
tubular carcinoma can be seen associated with invasive ductal carcinoma, NOS
type or sometimes with invasive lobular carcinoma, which leads to dilemma in
making a diagnosis. In such instances, the term tubular NOS and tubular mixed
can be employed. Mixed tubular carcinomas are associated with increased
tumour size, increased nodal metastases and worse clinical outcome.38
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Immunohistochemically, these tumours are 90% of these tumours are
positive for ER, 70-80% are positive for PR and rarely they show HER2
overexpression.
4. CRIBRIFORM CARCINOMA:
Invasive cribriform carcinoma is a relatively rare neoplasm of breast
which is similar to tubular carcinoma and shares a favourable prognosis with it.
This tumour shows a cribriform appearance of the invasive component,
reminiscent of the in situ counterpart, which is frequently associated with it.
Cribriform pattern is often associated with tubular formations, but the relative
proportion of both determines the terminology of the tumour, as proposed by
Page et al.,13
5. MUCINOUS CARCINOMA:
Mammary mucinous carcinomas are also described as colloid, mucoid, or
gelatinous carcinomas. It is characterized by the production of abundant mucin,
both intracellular and extracellular.
Macroscopically, these tumours are characteristically sharply
circumscribed, soft tumours with gelatinous and glistening cut surface.
Microscopically, the tumour cells are arranged in clusters and islands
composed of 10-20 cells in lakes of extracellular mucin. The mucin stains
positive with mucicarmine, MUC2 and MUC6. The term mucinous carcinoma is
employed only when at least 90% of the tumour shows mucinous appearance.39
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Immunohistochemically, these tumours are always positive for hormone
receptors whereas HER2neu is almost always negative.40
6. CARCINOMA WITH SIGNET-RING CELL DIFFERENTIATION:
Signet-ring cell carcinoma is a type of malignancy in which the cells show
abundant intracellular mucin which pushes the nucleus to one side of the cell,
resembling the characteristic signet-ring appearance. It is important that primary
invasive breast carcinomas with signet-ring cell morphology to be differentiated
from metastases from other organs.39
7. CARCINOMA WITH MEDULLARY FEATURES:
`The tumours of the breast which show medullary features are typically
associated with triple negative phenotype i.e., lack of expression of ER, PR and
lack of her2 amplification. These tumours have been found to be associated with
carriers of BRCA1 germ line mutation, which shows worse prognosis. The
medullary-like carcinoma is associated with expression of basal cytokeratins,
which leads to them being classified as basal-like breast cancers.41
Grossly, these tumours are well circumscribed and have soft and uniform
consistency.
Microscopically, there are three major morphologic criteria, for a tumour
to be classified as medullary-like carcinoma. They are, more than 75% of the
tumour cells to be arranged in syncytial network, absence of fibrosis, prominent
stromal lymphocytic infiltrates, lack of gland formation, and well circumscribed
tumour with pushing margins rather than infiltrative margins. The cells have
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abundant cytoplasm, pleomorphic vesicular nuclei with one or more prominent
nucleoli. Mitotic rate is high with numerous giant mitoses.33
8. METAPLASTIC CARCINOMA:
Metaplastic carcinoma represents a group of rare primary breast
malignancies, which exhibit either an admixture of epithelial and mesenchymal
components including chondroid, osseous, spindle cell and rhabdomyoid cells, or
purely the mesenchymal elements. Immunohistochemically, metaplastic
carcinomas have been found to be negative for ER, PR, her2neu expression and
they express basal cytokeratins like CK5/6 and EGFR.39
9. INVASIVE PAPILLARY CARCINOMA:
Invasive papillary carcinoma of the breast is a very rare neoplasm,
constituting about <1% of all breast malignancies.36 The major differential
diagnosis include papillary carcinoma in situ, encysted papillary carcinoma and
benign papilloma with ductal carcinoma in situ.33
The diagnostic criteria include the presence of papillary pattern of tumour
cells constituting more than 90% of the tumour area. Microscopically, the
invasive component of the tumour shows papillary architecture with
fibrovascular cores lined by malignant epithelial cells.39
10. INVASIVE MICROPAPILLARY CARCINOMA:
Pure micropapillary carcinoma is an extremely rare tumour, constituting
about <1% of all the tumours of breast. The histopathological appearance is
distinctive, with formation of pseudo papillary structures without the
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fibrovascular cores and tubular structures floating in clear empty spaces. The
tumour cell clusters exhibit a distinctive ‘inside out’ appearance due to the
inversion of polarity which can be evidenced by the pattern of MUC staining.
These tumours have increased propensity for lymphatic invasion with nodal
metastases and high local recurrence and are associated with a poorer
prognosis.42
Immunohistochemistry and genomic studies have identified that majority
of invasive micropapillary carcinomas express ER and have led to the
classification of these tumours as luminal A or B subtype.
11. CARCINOMA WITH APOCRINE DIFFERENTIATION:
It is a very rare tumour that constitutes about 0.5% of invasive breast
carcinomas. Apocrine differentiation has been found in association with invasive
carcinoma NST and various special type carcinomas including lobular, tubular,
papillary and medullary carcinomas. 32
Microscopically, it is characterized by cells with abundant granular
eosinophilic cytoplasm which is positive for PAS and diastase resistant or cells
with foamy cytoplasm due to intracellular lipid or both. The nuclei are enlarged
with prominent nucleoli.
Immunohistochemical staining shows characteristic ER and PR negativity
and HER2 positivity. They are positive for androgen receptor and GCDFP-
15.43,44
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12. SECRETORY CARCINOMA:
Secretory carcinomas are exceptionally rare in the breast and they account
for less than 0.15% of all breast cancers. It is primarily found in children and
young adults.32 Grossly, the tumour is usually small and well-circumscribed.
Microscopically, it shows three patterns including solid, tubular and microcystic.
The presence of both intracellular and extracellular rounded vacuoles of varying
sizes containing secretory material which stains positive with alcian blue and
PAS with diastase digestion is diagnostic of secretory carcinoma.
Immunohistochemically, secretory carcinomas are usually triple negative
that is ER, PR and HER2 negative along with p63 negativity.45
13. CARCINOMA WITH NEUROENDOCRINE FEATURES:
Primary neuroendocrine tumours of the breast constitute for about 1-4%
of all invasive breast malignancies. They are designated as neuroendocrine
carcinomas when the tumours express neuroendocrine markers in more than 50%
of its cell population.32
Histopathologically, these tumours are classified as well-differentiated
neuroendocrine carcinomas, poorly differentiated/ small cell carcinoma, invasive
breast carcinoma with neuroendocrine differentiation.
Immunohistochemical staining of these tumours shows expression of
chromogranin, synatophysin and neuron specific enolase. Electron microscopy
demonstrates the presence of dense core granules.33
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14. SPREAD RELATED VARIANTS:
INFLAMMATORY CARCINOMA:
The term inflammatory carcinoma is entirely based on the characteristic
clinical features in which the breast appears warm, red and shows edema of the
overlying skin, reminiscent of mastitis. The appearance of inflammatory
carcinoma is essentially due to the carcinomatous involvement of dermal
lymphatic channels. The occurrence of clinical inflammatory appearance may or
may not show microscopic dermal lymphatic invasion by tumour cells and its
reverse is also possible, wherein the tumour showing histopathologic permeation
by tumour cells, of the dermal lymphatic vessels may or may not have a clinical
inflammatory carcinoma.
The presence of microscopic dermal lymphatic invasion is a sign of poor
prognosis, irrespective of whether the patient has clinical features of
inflammatory carcinoma or not.13
According to a study by Charafe-Jauffret et al., inflammatory carcinoma
is found to be ER negative and positive for E-cadherin, MIB1, MUC1 and
HER2neu.
PAGETS DISEASE:
Paget disease of the nipple is a crusted lesion of the nipple that is almost
always associated with high grade ductal carcinoma in situ, with or without
stromal invasion. It occurs in about 2 % of all breast cancers, clinically
presenting as an eczematous or erythematous ulcerating rash of the nipple.
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Clinically, it is indistinguishable from benign eczematous dermatitis. Hence,
these patients should be thoroughly examined for breast malignancies.
Microscopically, the epidermis shows single or small clusters of large
pleomorphic cells with abundant, often clear cytoplasm, usually in the basal
layer. These cells stain positive for PAS positive diastase- resistant mucin.
Immunohistochemistry shows EMA, CEA, MUC1, CK7 and HER2
positivity, whereas the tumour cells are negative for high molecular weight
cytokeratins and melanoma specific markers such as S-100, HMB45 and
MELAN-A.13
PROGNOSTIC AND PREDICTIVE FACTORS IN BREAST CANCER
1. SIZE OF THE TUMOR:
The gross tumour size is one of the most significant independent prognostic
factors in breast cancers. With increasing size of the tumour, the incidence of
axillary nodal metastases increases and the survival decreases.
T1 Tumour≤20 mm in greatest dimension
T1mi Tumour≤1 mm in greatest dimension
T1a Tumour>1 mm but ≤5 mm in greatest dimension
T1b Tumour>5 mm but ≤10 mm in greatest dimension
T1c Tumour>10 mm but ≤20 mm in greatest dimension
T2 Tumour>20 mm but ≤50 mm in greatest dimension
T3 Tumour>50 mm in greatest dimension
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T4b Tumours that are of any size and show direct extension to the skin over
the breast resulting in ulceration.
T4d includes tumours of any size with permeation into dermal lymphatic
channels, which is an ominous prognostic sign and inflammatory carcinoma.
According to the Nottingham/Tenovus Primary Breast Cancer Study
(NTPBCS), the tumour size is considered an important independent variable and
hence it forms an integral component of the Nottingham Prognostic Index (NPI).
NPI is an important prognostic factor for management purposes, which
incorporates tumour size, lymph node status and histologic grade as a continuous
variable.36
2. LYMPH NODE METASTASIS
Lymph node status is one of the most significant independent prognostic
factors in breast carcinomas and it should be assessed on histopathological
examination rather than clinical examination.
Many studies have confirmed  that the patients who have microscopic
involvement of regional lymph nodes have a poorer prognosis than those without
regional node involvement.46 Furthermore, the prognosis depends on the number
of nodes involved, the presence or absence of extra nodal involvement and the
size of the nodal metastasis. 33
Lymph node staging is divided into three categories: stage 1 in which no
node is involved; stage 2 which shows involvement in up to 3 axillary lymph
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nodes or a single internal mammary node involvement; stage 3 tumours
which show 4 or more positive lymph nodes.
3. HISTOLOGIC TYPE
The tumours that belong to special types like tubular carcinoma,37
mucinous carcinoma,40 tubulolobular carcinoma,47 invasive cribriform
carcinoma,36 medullary carcinoma, classic lobular carcinomas are identified
to have better prognosis than invasive carcinoma, NST type.48 The variants
like pleomorphic lobular carcinoma, basal-like carcinomas and signet ring
cell type carcinomas, usually show a poorer prognosis.
4. HISTOLOGIC GRADE
The first description of histologic grading of ductal carcinoma was by
Greenhough in the year 1925.
The most commonly used grading system in the Scarff-Bloom-
Richardson grading system. It is based on three morphologic features namely,
tubule formation, nuclear grade and mitotic rate. It classifies breast
carcinomas into two major groups, which includes low grade and high grade
breast carcinomas.
Later, the Elston-Ellis modification of the Scarff-Bloom-Richardson
system was made and till date, this has been the most preferred grading
system all over the world, for the grading of breast cancers. This system uses
scoring system for the morphologic features and hence it is a semi
quantitative grading system. It uses score 1 to 3 for each of the features. It is
also called as Nottingham grading system.36 It is the recommended system for
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grading of breast cancer by various international bodies including world
health organization (WHO) and American joint committee of cancer
(AJCC).32
TABLE 1(A): SCORING OF TUBULE FORMATION
PERCENTAGE OF TUBULES WITHIN TUMOR SCORE
>75% 1
10-75% 2
<10% 3
TABLE 1(B): SCORING OF NUCLEAR PLEOMORPHISM
NUCLEAR FEATURES SCORE
Small, uniform nuclei 1
Moderate increase in size/ variation 2
Marked variation 3
TABLE 1(C): SCORING OF MITOTIC COUNT PER 10 HPF
FIELD DIAMETER
0.59MM/0.274mm2
FIELD DIAMETER 0.44
mm/0.152mm2
SCORE
0-9 0-5 1
10-19 6-10 2
>20 >11 3
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TABLE 1(D): FINAL GRADING OF NOTTINGHAM MODIFICATION
OF SCARFF BLOOM RICHARDSON SYSTEM
GRADE TOTAL SCORE DEGREE OF DIFFERENTIATION
I 3-5 Well differentiated
II 6-7 Moderately differentiated
III 8-9 Poorly differentiated
The Nottingham grading of breast cancer is used along with tumour size
and lymph node stage in the Nottingham prognostic index, and is a effective tool
for stratification of treatment strategies for various prognostic groups of
patients.33
5. ANGIOLYMPHATIC INVASION:
Lymphovascular invasion is one of the most significant prognostic factor in
breast cancers, as it is one of the important step in the pathogenesis of metastatic
breast cancer, leading to increased morbidity, mortality and decreased long-term
survival of the patient.49 Histopathologically, the lymphovascular invasion is
assessed using Haematoxylin and Eosin stained sections of tumour and
peritumoral region. The presence of tumour cells within the lumen of
intratumoral and peritumoral lymphatics and blood vessels which are lined by
endothelial cells is considered to be positive for lymphovascular invasion. But,
whether the emboli are involving a blood vessel or lymphatic channel, cannot be
differentiated by routine histopathological examination. The use of
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immunohistochemical stains specific for endothelial cells of lymphatics, like D2-
40 and anti-podoplanin is applied for differentiating blood vessel and lymphatic
emboli50.
Lymphatic  invasion has been observed in 44% of LN negative and 86% of
LN positive accounting to  66% of overall breast cancer patients, as
demonstrated by Kahn et al.,51,52
The presence of blood vessel invasion is associated with an increased risk of
early recurrence in operated lymph node negative breast cancer patients. Thus,
lymphovascular invasion forms an important predictive factor for local
recurrence and nodal metastasis after conservative surgeries in early breast
cancers and flap recurrence in mastectomised patients.53
6. TUMOR NECROSIS
Spontaneous tumour necrosis is associated with high histologic grade and
earlier lymph node metastasis. It is also associated with decreased long term
survival.
Tumour necrosis is commonly seen in tumour of ductal type with high histologic
grade and basal phenotype.13
7. STROMAL FEATURES
Tumours which show absence or decreased inflammatory infiltrates at the
invasive front are associated with better prognosis, lesser incidence of lymph
node metastasis and survival.13
Stromal fibrosis has been associated with variable prognosis, according to
various semi-quantitative studies, from favourable outcome to poor disease-free
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survival. Stromal elastosis is yet another variable stromal elastic fibres in cases
of breast cancer. Elastosis can be periductal or diffuse in nature. Stromal
elastosis, by itself is not an independent prognostic factor, though some studies
have shown good prognosis in cases with elastosis.
8. INSITU COMPONENT
Some studies have shown that the presence of prominent in situ
component associated with invasive carcinomas bodes better prognosis and
decreased lymph node metastases.
9. OTHER HISTOLOGIC PROGNOSTIC FACTORS
INFLAMMATION
Prominent lymphocytic or lymphoplasmacytic infiltration has been
associated with good prognosis. Grade 3 ductal carcinoma NST with prominent
inflammation has been found to have better prognosis than grade 3 ductal
carcinoma NST without prominent inflammation. 54
MICROVESSEL DENSITY
Increased microvascular density is found to be associated with earlier
lymph node metastasis and decreased long-term survival in node-negative
carcinomas.55
APOPTOTIC INDEX
Apoptosis is characterized by shrinkage of cells and pyknotic and
karyorrhectic nuclei with cytoplasmic blebbing. Apoptotic index is counted on
H&E stained sections similar to mitotic index. Immunohistochemical stains can
also be used to count mitotic index, like caspase 1 and 3 annexin V cleaved
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CK18 and CD95, and terminal deoxynucleotidyl transferase–
mediateddigoxigenin-11–deoxyuridine triphosphate nick end labeling (TUNEL)
method. Although High apoptotic index is associated with higher grade of
tumour, higher proliferative activity and lack of expression of hormone
receptors,56 it does not qualify to be an independent prognostic factor for breast
cancers. 57
PERINEURAL INVASION
Perineural invasion is found in about 10-25% of breast carcinomas and is
associated with high grade tumours and lymphovascular invasion. But it is not
proved to be independently associated with prognosis.
IMMUNOHISTOCHEMICAL TUMOR MARKERS:
HORMONE RECEPTORS
Estrogen and progesterone are steroid hormones that play an important
role in the normal glandular development and in breast cancer progression. The
presence of hormone receptors namely estrogen and progesterone receptors, in
the tumour tissue of breast correlates with the response to hormonal and
chemotherapy. Estrogen and progesterone mediate their effects on breast tissue
by binding to specific nuclear receptors, leading to transcriptional regulation
(activation or repression) of target genes58. Estrogen receptor occurs in two
different forms namely ɑ and β. While ERɑ plays an important role in ductal
elongation during puberty, PR and ERβ are important for lactational
development of lobules59.
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Studies have found that ER-negative breast malignancies are associated
with histologic grade 3, pushing margins, comedo-necrosis, central fibrosis and
lymphocyte-rich stroma60. Mucinous carcinoma, tubular and lobular carcinomas
are associated with increased ER-positivity whereas most of the cases of
medullary, apocrine and metaplastic carcinomas show ER-negativity.32
ER is positive in 70% - 95% of invasive lobular carcinomas and 70% -
80% of invasive ductal carcinomas, whereas PR is positive in 60%- 70% of
invasive breast carcinomas61. Although the presence of ER and PR in an
invasive breast carcinoma is considered as an independent prognostic and
predictive factor48,62 ; Liu et al., 2010), both lose their prognostic value after
long-term follow-up.63–65
Hormone receptors are evaluated in formalin fixed paraffin-embedded
breast tissues using various methods including immunohistochemistry,
fluorescent in situ hybridization and PCR,13 of which immunohistochemistry is
the most widely used technique.
ASSESSMENT OF HORMONE RECEPTORS:
Immunohistochemical assessment of hormone receptors is performed by
using two parameters, namely the number of positively stained tumour cell
nuclei and the intensity of staining. Many scoring systems have been proposed
for assessing both the parameters, of which Allred scoring system is the simpler
and most widely accepted and recommended method. The number of stained
tumour cell nuclei is expressed as percentage of total tumour cell population.
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TABLE 2(A): SCORING OF PROPORTION OF STAINED NUCLEI
SCORE FOR PROPORTION OF
POSITIVE NUCLEI
PERCENTAGE OF STAINED
TUMOR CELL NUCLEI
0 No staining
1 <1%
2 1-10%
3 11-33%
4 34-66%
5 67-100%
TABLE 2(B): SCORING OF INTENSITY OF STAINING
SCORE FOR INTENSITY INTENSITY OF STAINING
0 No staining
1 Weak staining
2 Moderate staining
3 Strong staining
Both the score for proportion of stained cell nuclei and score for intensity of
staining are summed up to give a maximum score of 8.66
The presence of these steroid receptors has been found to be very
powerful predictor of response to breast cancer hormonal therapy and has
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significantly improved the long term clinical outcomes of patients with ER/PR-
positive tumours. The response rate to cancer hormonal therapy for ER/PR
positive tumours is approximately 80%67,68.  ER- positive tumours show better
prognosis and show good response to adjuvant chemotherapy with tamoxifen13.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2 (Her2)
The human epidermal growth factor receptor 2 (HER2) is a
transmembrane tyrosine kinase receptor, homologous to the epidermal growth
factor receptor and is encoded by the gene ERBB2 on chromosome 17q12.69
Her-2 amplification and/or overexpression is observed in about 15-30% of
human breast cancers leading to increased activity of tyrosine kinase and
downstream pathways stimulating tumour growth.70 It is associated with
clinically aggressive nature of tumour with morphologically high histologic
grade, negative ER status, increased rates of recurrence and mortality. The
prognosis of patients with her-2 positive tumours has been found to be
significantly worse than those with her-2 negative tumours71,72.
The development of targeted chemotherapy using anti-Her2 monoclonal
antibody Trastuzumab (Herceptin) is a major breakthrough in the management of
breast cancers. Trastuzumab is useful in the treatment of early stage breast
cancers and has been found to reduce the risk of  recurrence after surgery73.
Various studies have shown that the use of Trastuzumab with chemotherapy in
advanced breast cancers and metastatic disease has shown increase in overall
response rates, decrease in risk of death, longer disease free survival and longer
duration of disease progression72,74–76.
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The Her-2 status of the patient is essential for the treatment of
Trastuzumab.
The assessment of Her-2 status in breast cancers can be done by using
immunohistochemistry and fluorescent in situ hybridization (FISH). IHC
identifies Her-2 receptor on the cell membrane whereas the Her-2 gene is
quantified in FISH77,78. On immunohistochemistry, the results for Her-2 testing
are classified as positive, equivocal or negative. The most recent guidelines for
Her-2 testing and scoring from American Society of Clinical Oncology and
College of American Pathologists (ASCO/CAP) have recommended the
following interpretation:
A score of 3+ on IHC staining (intense, uniform circumferential staining)
in ≥30 % of tumour cells or FISH indicating more than six gene copies per
nucleus, or a FISH gene ratio (ratio of Her-2 gene signals to chromosome 17
signals) equal to or greater than 2.2 indicates a positive result. A score of 0 or 1+
on IHC staining ( no staining or weak, incomplete membrane staining in any
proportion of tumour cells, a FISH result of less than 4 Her-2 gene copies per
nucleus, or a FISH gene ratio of less than 1.8 indicates a negative result.
Equivocal result is indicated by a score of 2+ on IHC staining (complete
membrane staining that is either nonuniform or weak in intensity but with
obvious circumferential distribution in at least 10% of cells). Equivocal IHC
samples must be referred to further FISH testing for confirmation.79
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PROLIFERATION MARKERS
Tumour proliferation is one of the hallmarks of cancer, which indicates
the cell cycle disruption and imbalance between cell proliferation and cell death.
Various markers have been identified to evaluate tumour proliferation including
S-phase fraction, thymidine labeling index, mitotic count, and
immunohistochemical staining for Ki67, cyclin, topoisomerase IIɑ, proliferating
cell nuclear antigen (PCNA) and geminin. High S-phase fraction is strongly
associated with high grade of tumour, ER negativity and Her-2 overexpression,
which also contribute to worse prognosis. Mitotic count, which is the number of
mitoses in a given area of tumour, has been included in all grading systems of
breast cancer and is considered the simplest tool to evaluate proliferation on
H&E stained sections 67,80–82.
Ki-67 is the most widely accepted and preferred proliferation marker,
which is assessed immunohistochemically using antibodies directed against it. It
is present in actively proliferating cells83. Ki-67 is evaluated on paraffin-
embedded tissue sections using monoclonal antibody MIB-1 and it is expressed
as the percentage of stained tumour cell nuclei84. The grading protocol for KI-67
has not yet been standardized and various studies have used different cut-off
percentages for high Ki-67 index85,86. St. Gallen International Expert Consensus
has advised to classify Ki-67 index into 3 categories as follows: high Ki-67 index
when ≥30%, low when immunopositivity <15% and intermediate when
immunopositivity is between 16 to 30%87,88. Although high Ki-67 is associated
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with worse clinical outcome, shorter overall and disease free survival, it is still
not recommended as prognostic marker89.
MOLECULAR CLASSIFICATION OF BREAST CANCER
Conventionally, breast cancers have been classified based on
morphological characteristics until the year 2000, when Perou and colleagues
first described the genomic and molecular nature of breast cancers based on
cDNA microarray and gene expression profiling. They demonstrated that the
expression pattern of a set of genes within the tumour determine the molecular
signature of breast cancer and that the intrinsic molecular signatures predict the
clinical outcome of the disease6,7. Breast cancers can be broadly classified into
ER – positive and ER- negative which are further divided into five molecular
subtypes:
1. Luminal A
2. Luminal B
3. Her-2 overexpressing
4. Basal-like
5. Normal breast-like.6,7
Luminal A tumours have the best prognosis and basal and Her-2 positive
tumours have the worst prognosis7,90. The luminal A subtype is the most frequent
type constituting about 24%-39% of breast cancers, followed by basal-like (17%-
37%), luminal B (10%- 18%), HER2 (4-10%) and normal-like (0-5%)91,92.
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FIGURE 2: HIERARCHICAL CLUSTERING OF 115 TUMOUR
TISSUES AND 7 NON-MALIGNANT TISSUES USING THE
“INTRINSIC” GENE SET. EXPERIMENTAL DENDROGRAM SHOWS
THE CLUSTERING OF THE TUMOURS INTO FIVE SUBGROUPS.
BRANCHES CORRESPONDING TO TUMOURS WITH LOW
CORRELATION TO ANY OF THE SUBTYPE ARE SHOWN IN
GREY. 91
TABLE 3: RECEPTOR STATUS OF MOLECULAR SUBTYPES OF
BREAST CANCERS
MOLECULAR SUBTYPE RECEPTOR STATUS
Luminal A ER+/PR+/HER2-
Luminal B ER+/PR+/HER2+
HER2 overexpressing ER-/PR-/HER2+
Basal-like ER-/PR-/HER2-
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TABLE 4: FEATURES OF THE MOLECULAR SUBTYPES OF BREAST
CANCER 93
MOLECULAR
SUBTYPE
FRE
QUE
NCY
CELL OF
ORIGIN
ER/PR/
HER2
PROLIFE-
RATION
RATE
HISTO
LOGIC
GRADE
PROGNOSIS
Luminal A 50-
60%
Luminal
epithelial
cell
ER
and/or PR
+ve, Her-
2 –ve
Low Low Excellent
Luminal B 10-
20%
Luminal
epithelial
cell
a)Her-2-
ve, ER
and/or PR
+ve
b) Her-
2+ve, ER
and/or PR
+ve
a) High b)
Any
Interme
diate/
High
Intermediate/
Bad
HER-2
overexpressing
10-
15%
Late
luminal
progenitor
cell
Her-2
+ve ER -
ve and
PR –ve
High High Bad
Normal breast-
like
5-
10%
Luminal
epithelial
cell
ER -
ve/+ve
Her-2 -ve
Low Low Intermediate/
good
Basal-like 10-
20%
Basal/
myoepithe
lial cell/
bipotent
progenitor
ER -ve,
PR -ve,
and Her-2
-ve
High High Bad
Luminal A tumours are characterized by higher levels of ER and PR
expression, negative expression of HER2, low Ki67 staining, and expression of
luminal epithelial cytokeratins CK8 and 18 by IHC94. Luminal A tumours
frequently exhibit low histological grade, and good prognosis95.
Luminal B tumours are also ER-positive and express CK8 and 18. They
are frequently associated with a more aggressive phenotype and worse prognosis,
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higher histological grade, lower PR expression, and exhibit higher Ki67
staining95,96
HER2+ overexpressing tumours are found to be associated with high
tumour proliferation, high histological grade, and frequent p53 mutations97.
Triple negative breast cancer (TNBC) subtype is one of the breast cancer
subtype which constitutes about 10 to 20% of tumors95.  These tumours show
lack of expression of ER, PR, or HER2. Basal-like breast tumours show
expression of basal/ myoepithelial markers, such as CK 5/6, 14, and 1798.
TNBCs account for about 75% of all BRCA1-deficient tumours, frequently
associated with p53 mutations, exhibit genomic instability, show high
histological grade, and high Ki67 positivity95.
Thus, molecular classification using gene expression profiling has
produced a paradigm shift in the understanding of the pathology, clinical
outcome and prognosis of breast cancers and has been applied in the
development of targeted therapy for use as part of personalised medicine.
MULTIGENE PROGNOSTIC AND PREDICTIVE TESTS
Many studies have led to the development of commercialized multigene
assays for the prognostication and selection of treatment for individual patients99.
These include Oncotype DX and MammaPrint genomic tests.
The Oncotype DX is a reverse transcription polymerase chain reaction
(RTPCR)-based assay that analyses a panel of 21genes expression in formalin
fixed paraffin-embedded tumour tissues. It was formulated to predict the
likelihood of disease recurrence in patients with node-negative, ER+ breast
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cancer who undergo treatment with Tamoxifen. The 21 genes are associated with
ER pathway, proliferation, HER2 and invasion, and determines a risk of
recurrence (ROR) score ranging from 0 to 100, which is an independent
prognostic factor.100 The Oncotype DX is the most widely used molecular test in
the clinical setting for making treatment decisions and is recommended by the St.
Gallen Consensus101.
Mamma-Print® is one another commercially available 70-gene test that
provides prognostic information for patients with stage 1 or 2, node-negative
invasive breast cancer of tumour size < 5 cm. It quantifies the risk of metastasis
in early breast cancers and divides patients into two groups- low and high risk of
recurrence irrespective of ER status and prior chemotherapy102.
Other commercially available prognostic signatures are 76-gene signature
named as Veridex, breast cancer index and PAM50 signature.
TRIPLE NEGATIVE BREAST CANCER
Triple negative breast cancers are defined by the negative expression of
estrogen receptor, progesterone receptor and lack of overexpression and
amplification of HER2 gene. They account for about 10-20% of all breast
cancers and also account for most of the deaths due to breast cancer8. These
tumours have been found to show poor prognosis despite good response to
neoadjuvant chemotherapeutic agents and lack of targeted therapy103.
EPIDEMIOLOGY
TNBC more frequently affects younger patients(<50 years),104–106 more
prevalent in African-American women, increased incidence of distant visceral
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metastases and a unique mechanism of haematogenous spread, more frequently
presents as interval cancers between consecutive mammograms and are more
aggressive than tumours of other molecular subgroups104,106. TNBC accounts for
39% of all breast cancers that occur in pre-menopausal African-American
women under the age of 50 years, whereas only 16% of breast cancers that are
diagnosed in Caucasian women of the same age group. It has been observed that
about 14% of breast cancers occurring in post-menopausal African-American
women are found to be TNBC107. More than 75% of breast cancers arising from
a mutation in BRCA1 gene belong to triple-negative phenotype, basal-like
subtype or both8,108.
PATHOLOGIC FEATURES
The prototypical features of triple negative breast cancers are summarised in the
table 5.
TABLE 5: PROTOTYPICAL FEATURES OF TRIPLE NEGATIVE
BREAST CANCER109
Morphological
features
High histologic grade
Lack of tubule formation
Prominent nuclear abnormalities
High mitotic count
Broad pushing borders
Necrotic and fibrotic areas
Prominent lymphoplasmacytic infiltrate
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Biological features Lack of expression of ER and PR
HER2 negative
High Ki-67 index
P53 mutation
Positive immunostaining for basal cytokeratins,
vimentin,
p-cadherin, EGFR, PDGFR, IGF-IR and c-kit
Molecular
classification
Most commonly basal-like
Histologically, TNBC are often high grade tumours with lack of tubule
formation, high mitotic count and high nuclear atypia48,104. They show broad
pushing margins and more commonly have large areas of necrosis, fibrosis and
prominent lymphocytic infiltrate. Most of the TNBC are high grade invasive
ductal carcinoma, no special type, metaplastic carcinoma and medullary
carcinomas.110,111.Methylated BRCA1 promoter region has been found in
medullary and metaplastic types of breast cancer112. There is no convincing
association between the prevalence of lymph node involvement at the time of
diagnosis and triple negative breast cancers, as various studies show varying
results8. Only a weak correlation has been observed between tumour size and
lymph node metastasis in triple negative breast tumours in a study conducted by
Dent et al.104.
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MOLECULAR SUBTYPES OF TNBC
Lehmann et al have identified 6 different molecular subtypes of triple-
negative breast cancer based on gene expression profiling of TNBC including
Two basal-like (BL1 and BL2),
Immunomodulatory (IM),
Mesenchymal (M),
Mesenchymal stem-like (MSL), and
Luminal androgen receptor (LAR) subtypes.
These subtypes are thought to be driven by various distinct pathways
which can be effectively targeted by specific drugs113.
CLINICAL COURSE AND OUTCOME
Triple-negative breast cancers are generally aggressive with shorter
disease-free interval with adjuvant chemotherapy and aggressive clinical course
with earlier nodal and distant metastases with significant shortening of overall
survival of the patients, despite their sensitivity and response to initial adjuvant
and neoadjuvant chemotherapy with taxanes and anthracyclines103.
BASAL-LIKE BREAST CANCER
Basal-like breast cancer have been identified by the hierarchical clustering
of the variations in the gene expression profile of 496 genes, which is called the
“intrinsic subset”6. Approximately 80% of triple negative breast cancers are
basal-like breast cancers114 and they account for about 15% of all breast cancers6.
It is a unique and aggressive breast cancer subtype7. Basal-like breast cancers
arise from epithelial/ myoepithelial progenitor stem cell of breast115.
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Although most of the triple negative breast cancers and basal-like
carcinomas are of high histologic grade, a small subset of them belong to low
histologic grade like secretory carcinoma, acinic cell, adenoid cystic and
apocrine carcinomas.
EPIDEMIOLOGY AND CLINICAL FEATURES
Basal-like breast cancer is found to be seen more frequently in women
who attain early menarche, women who are overweight and obese, high parity
and women who had breastfed for a shorter duration during their lifetime108.
IMMUNOHISTOCHEMICAL FEATURES
The knowledge of basal cytokeratins CK5/6, CK14 and CK17 expression
in basal-like tumours have been acquired only recently7, although the
immunohistochemical expression of basal cytokeratins in the breast was
demonstrated as early as 1982116. They express basal cytokeratins such as CK5,
CK6, CK14, CK8/CK18,p63, EGFR, P-cadherin, vimentin, aB crystallin, fascin
and caveolin1 and 27,41. These tumours more commonly affect younger patients,
about 82%  of basal-like cancers show either immunohistochemical expression
of p53 or TP53 mutation as compared to only 13% of luminal-A tumours show
p53 expression7and high proliferation index. About 60% of basal-like tumours
express EGFR on the cell surface41,110.
Many studies have found an association between vimentin expression and
aggressive phenotype of breast malignancies. Livasy et al observed a strong
expression of vimentin in about 94% of basal-like tumours. The expression of
vimentin is attributed to the origin of tumours from myoepithelial cells,
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epithelial-mesenchymal transition due to dedifferentiation of tumours and origin
of tumours from breast cancer stem cells117.
The expression of luminal cytokeratins CK8/18, which are expressed in
luminal epithelial cells of the breast and the normal myoepithelial cells do not
express these luminal markers. Livasy et al observed a strong expression of
luminal cytokeratin CK8/18 in about 83% of basal-like tumours, suggesting an
origin from breast cancer stem cells which undergo varying degrees of basal and
luminal differentiation. These tumours are called as basoluminal subtypes117.
Since the basal cytokeratins are normally expressed by the basal cell layer
of the breast epithelium, these tumours are called with the suffix “basal”. These
tumours are called by various terminologies such as basal-like, basal cell
phenotype, basal phenotype, basal epithelial phenotype and basal type in the
literature. The term ‘basal-like’ usually refers to the cDNA microarray based
classification, whereas the other terms are used in immunohistochemical studies.
GENE EXPRESSION OF BASAL CLUSTER
Basal-like cluster in gene expression profiling of breast cancers have
found expression of EGFR, c-Kit, cyclin E, basal cytokeratins CK5/14/17,
vimentin, P-cadherin, caveolin 1 and 2, alpha B crystalline, TP53 mutations and
genomic instability with inactivation of RB pathway112,118.
BRCA1 MUTATION AND TNBC
Abnormal BRCA1 function due to epigenetic alterations by methylation
of BRCA1 promoter region has been observed in triple-negative basal-like breast
cancer. The BRCAness i.e. BRCA-associated breast cancer subtypes are
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characterised by higher grade at diagnosis, lack of expression of ER and Her-2,
amplification of c-myc, medullary type with pushing margins, less common
DCIS, TP53 mutations, lymphocytic infiltrate showing basal phenotype and
expression of EGFR112.
IMMUNOHISTOCHEMICAL MARKERS AS SURROGATES FOR
MOLECULAR SUBTYPING
Immunohistochemistry (IHC) is a well-established, powerful diagnostic
tool which is suitable for use in archival FFPE tissues. Compared to gene
expression profiling, IHC is more feasible logistically for routine diagnostic
histology laboratories, and it has been validated in multiple studies. The basal
subtype of breast tumours specifically has been the subject of interest in many
studies attempting to characterise it by IHC. Nielsen et al. used the markers ER,
HER2, the basal cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor
(EGFR, also known as HER1) to detect basal-like subtype of breast tumors41.
Basal tumours were identified immunohistochemically as ER negative, HER2-
negative, and CK5/6 and/or EGFR-positive.
CK5/14/17 are currently the most widely accepted basal cytokeratins to
identify basal-like tumours by immunohistochemical methods and to distinguish
from luminal cytokeratins CK8/18/19 expressing tumors119–122. Some studies
have been done to assess the usefulness of immunohistochemical expression of
other myoepithelial markers such as p63, a p53 homolog and smooth muscle
actin on the tumour cells121,123. Livasy et al studied the immunohistochemical
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detection of various biomarkers and have found that smooth muscle actin, p63
and CD10 are of limited value in the identification of basal-like tumors117.
FUTURE THERAPEUTIC TARGETS IN TNBC
Although triple-negative breast cancers show initial response to
chemotherapy, they exhibit high incidence of relapse and distant visceral and
bone metastases with aggressive clinical course. Hence, it is important to identify
newer therapeutic targets. Currently, several studies are investigating the novel
targets like EGFR, Poly ADP- ribose polymerase (PARP), VEGF and breast
cancer stem cells.
Recent studies have shown that the triple-negative breast cancer subtype
has higher frequency of EGFR expression than non-TNBC subtypes. The EGFR
status negatively correlates with the overall survival in TNBC patients
suggesting that EGFR could be a potential target for chemotherapy with EGFR
inhibitors124.
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MATERIALS AND METHODS
The study was conducted in the Department of Pathology, Tirunelveli
Medical College and Hospital, Tirunelveli, after being approved by the
Institutional
Ethics Committee of Tirunelveli Medical College, Tirunelveli prior antecedent to
conducting the study. The study was carried out during the period September
2014 to September 2016 for 2 years.
RESOURCES
A total of 50 female patients with histopathologically proven triple-
negative primary breast carcinomas were who underwent modified radical
mastectomies were selected based on the status of negative immunoreactivity for
ER, PR and HER-2. The samples were received in the department of pathology,
Tirunelveli medical college, Tirunelveli. The archival tissue blocks of formalin-
fixed paraffin embedded tissues were retrieved for the study. Detailed histories
and clinical examination findings were obtained from the medical records
department. Tissue sections of 4-5μm thickness were stained with haematoxylin
and eosin stain. The tumours were classified based on WHO classification of
breast tumours and graded using modified Scarff-Bloom-Richardson grading
system.
SAMPLE SIZE
A total of 50 female patients with triple-negative primary breast
carcinomas were selected.
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INCLUSION CRITERIA
All histologically proven cases of primary breast malignancies that had
undergone resection surgeries.
EXCLUSION CRITERIA
Cases which show positivity for any of the markers ER, PR and Her-2.
MATERIALS REQUIRED
1. Archival formalin-fixed paraffin-embedded tissue blocks of primary
breast carcinomas.
2. Haematoxylin and eosin stained tissue sections made from the tissue
blocks.
3. Microtome and incubator for obtaining tissue sections and to dewax the
sections
4. Positively charged slides for holding tissue sections for IHC.
5. Reagents for preparing buffer solutions for antigen retrieval and washing
during staining procedure.
6. Microwave oven for antigen retrieval.
7. The PathnSitu universal immunohistochemistry kit for performing
immunohistochemical staining along with primary
antibodies for ER, PR, HER 2, CK5/6, EGFR.
8. Microscope, used for interpretation of histologic parameters and grading
of IHC.
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METHODOLOGY
1. The detailed clinical history and examination findings were obtained from the
medical records department.
2. SECTION CUTTING
Seven tissue sections of 4-5μm thickness were obtained from each of the
paraffin block, on poly-L-lysine (PLL) coated slides followed by dewaxing by
incubation of the slides at 60-70̊ C for one hour.
3. HAEMATOXYLIN AND EOSIN (H & E) STAINING
H and E staining was performed in The Department of Pathology, Tirunelveli
medical college, Tirunelveli. The tissue sections were first de-waxed and
rehydrated using graded alcohols and brought to water. Staining with Harris’s
haematoxylin was carried out for 10 minutes to stain all the nuclei. The sections
were then washed for 5 minutes under running tap water for blueing,
counterstained in 1% aqueous Eosin for 8 dips and then washed in tap water. The
sections were dehydrated, cleared and mounted. Results: cytoplasm- pink and
nuclei-dark blue.
The haematoxylin and eosin stained sections of breast carcinomas were
evaluated in detail, to the histopathological parameters such as histologic type,
histologic grade, tumour necrosis, angiolymphatic invasion, perineural invasion,
associated in situ component, stromal reaction, status of the margins, skin, nipple
and areola, and lymph node involvement. The histologic type was determined
according to the WHO classification of breast tumours. The histologic grade was
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given according to the Nottingham modification of the Scarff- Bloom-
Richardson grading system.
4. IMMUNOHISTOCHEMISTRY
Immunohistochemistry is the technique for localization of antigens or
proteins in tissue sections by the use of labelled monoclonal antibodies as
specific reagents through antigen-antibody interactions that are visualized by a
marker such as fluorescent dye. IHC is used for both diagnostic and biological
research purposes.
BUFFER SOLUTIONS
The buffer solutions were used for antigen retrieval and as wash buffer
according to the manufacturer’s guidelines (PATHNSITU).
1. Tris EDTA at a pH of 9 for all the used IHC markers.
2. Tris wash buffer at pH of 7.6 for both.
One representative tissue section was selected and immunohistochemical
staining was performed for ER, PR and Her-2. The staining was performed by
DAKO envision method according to the manufacturer’s guidelines.
DE-WAXING AND REHYDRATION
The tissues were de-waxed by soaking slides in xylene for 2 changes, 15
minutes each to remove the excess wax from the sections, and rehydrated by
placing in descending grades of alcohol- 100% ethanol for 2 changes, 5 minutes
each, 90% ethanol for 5 minutes, 70% ethanol for 5 minutes, followed by a wash
in distilled water for 2 changes, 2 minutes each.
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ANTIGEN RETRIEVAL
Antigen retrieval was performed by heat treatment using microwave
method. For heat treatment, a TRIS EDTA buffer solution pH9 (PathNSitu) pre-
heated in a glass coplin jar in a microwave on full power following which the
slides were immersed into the solution and allowed to boil for 15-20 minutes.
Following heat treatment, the slides were cooled in the solution at room
temperature for at least 15 minutes and then rinsed in TRIS wash buffer for 2
changes, five minutes each.
PREVENTION OF ENDOGENOUS STAINING
To prevent endogenous peroxidase activity, the slides were treated with a
ready- to- use peroxidase-blocking hydrogen peroxide solution (PathNSitu) for 5
minutes and then washed once in TRIS wash buffer for 2 changes, five minutes
each.
INCUBATION WITH PRIMARY ANTIBODY
The primary antibody is applied to the tissue sections and incubated in a
humidified moist chamber at room temperature for 30 minutes.
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TABLE 6: BIOMARKERS USED IN IHC
ANTIBODY SPECIES CLONE DILUTION
ER Rabbit
monoclonal
EP1 Ready to use
PR Rabbit
monoclonal
EP2 Ready to use
Her-2 Rabbit
monoclonal
EP3 Ready to use
CK5/6 Rabbit
monoclonal
EP24/EP67 Ready to use
EGFR Rabbit
monoclonal
EP22 Ready to use
E-Cadherin Rabbit
monoclonal
EP6 Ready to use
The slides were then washed in TRIS wash buffer for 2 changes, 10
minutes each. An amplifier- Polyexcel target binder reagent was then applied to
the sections and kept for 15 minutes followed by washing in TRIS wash buffer
for 2 changes, 2 minutes each.
INCUBATION WITH SECONDARY ANTIBODY
The secondary antibody used was Polyexcel Horse Radish Peroxidase
Polymer (HRP) as prescribed by the manufacturer, and incubated for 12 minutes,
in a humidified chamber at room temperature.
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VISUALISATION OF POSITIVITY USING DAB CHROMOGEN
The colorimetric detection of signal to detect antigen-antibody reaction
was achieved by the Diamino-benzidine tetrachloride DAB method. The working
solution of DAB chromogen from the DAB kit (PathNSitu) was prepared by
mixing 1 drop of DAB chromogen in 1 ml of DAB substrate buffer immediately
before use. This DAB solution was applied to the tissue sections at room
temperature and the development of colour was monitored for 2-5 minutes until a
brown staining of the section was visualised. The slides were then washed in
distilled water for 2 changes.
COUNTERSTAINING, DEHYDRATION, CLEARING AND MOUNTING
OF SLIDES
The slides were counterstained by immersion in Harris’s Haematoxylin
for 30 seconds. They were then washed thoroughly under running tap water for
blueing until clear. The slides were then dehydrated by immersing in ascending
grades of alcohol- 70% ethanol for 30 seconds, 95% ethanol for 30 seconds,
followed by 100% ethanol for 1 minute. The sections are cleared by soaking in
xylene for 2 changes, 2 minutes each. The slides were then mounted with cover
slip using DPX mounting solution for viewing under microscope.
STAINING PATTERNS OF VARIOUS ANTIBODIES
The positive immunostaining for ER and PR was observed in the nucleus
of the tumour cells, Her-2 and E-Cadherin positivity was observed in the plasma
membrane and CK5/6 immunostaining was seen in the cytoplasm while EGFR
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positivity was observed in the cytoplasm and membrane of the tumour cells. The
colour of staining for all six antibodies was brown.
USE OF CONTROL TISSUE SECTIONS
A positive tissue control was examined to confirm that all reagents were
functioning properly. A positive reaction was confirmed by the brown staining
due to the DAB chromogen labelling the antigen-antibody complex at the site of
the target antigen. If the positive control tissues fail to demonstrate the expected
staining pattern, all results with the test specimen were considered invalid.
IMMUNOHISTOCHEMICAL EVALUATION AND SCORING SYSTEMS
SCORING FOR ESTROGEN AND PROGESTERONE RECEPTORS
The scoring of ERɑ and PR were done according to the Allred scoring
system, this system employs the proportion and the intensity of the stained
nuclei66. The score for the proportion of stained nuclei was given on a scale of 0-
5 and the intensity of staining was given a score on a scale of 0-3. The total score
was calculated by adding the scores for proportions and intensities to give a total
score of 0 or 2 as minimum and 8 as maximum score. A total score of 3-8 was
considered as positive immunoreactivity whereas a score of ≤2 was regarded as
negative66.
SCORING FOR HER-2NEU
The scoring for Her-2 was based on the proportion and intensity of
staining of the plasma membranes of the tumour cells as per the ASCO/CAP
recommendations79.
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SCORING FOR CYTOKERATIN (CK5/6)
Cytokeratin 5/6 was scored as positive if any faint or strong cytoplasmic
and/or membranous immunostaining was observed in the neoplastic tumour
cells125.
SCORING FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
EGFR was scored as positive if more than 1% of the tumour cells showed
membrane immunoreactivity of any intensity125.
STATISTICAL ANALYSES
In this study, we used descriptive statistical analyses and Chi square test
using contingency tables for correlation studies. A P value of< 0.05 was
considered as significant.
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OBSERVATION AND RESULTS
PATIENT CHARACTERISTICS
A total of fifty cases of triple-negative breast carcinoma in south-Indian
female patients were studied. The results are as follows:
AGE
Patients’ age ranged from 22-70 years with a mean of 50.4±9.7 years. A
majority of the patients in the study population were under the age category of
≥ 50 years at the time of diagnosis (fifth decade).
CHART 1: AGE DISTRIBUTION OF THE PATIENTS (n= 50)
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LARGEST TUMOR DIAMETER
The tumour size was assessed using the largest diameter of the tumour
according to the TNM staging system. The tumours were classified into three
groups: ≤2 cm, 2-5 cm and ≥ 5 cm. Among our study population 10 cases (20%)
were ≤ 2 cm in diameter, 32 cases (64%) were 2-5 cm in size and 8 cases (16%)
were ≥ 5 cm in largest dimension.
CHART 2: DISTRIBUTION OF CASES ACCORDING TO THE TUMOR
LARGEST DIAMETER
10
32
8
0
5
10
15
20
25
30
35
<2 cm 2-5 cm >5 cm
N
o.
 o
f c
as
es
Tumor largest diameter (cm)
61
HISTOLOGICAL PARAMETERS
HISTOLOGIC TYPE OF TUMOR
Of the 50 cases studied, the predominant histologic type was infiltrating
ductal carcinoma, NOS type in 46 cases (92%). 2 cases (4%) were invasive
lobular carcinoma, 1 case (2%) was medullary carcinoma and 1 case (2%) was
atypical medullary carcinoma.
TABLE 7: DISTRIBUTION OF SAMPLES BASED ON HISTOLOGIC
TYPE
HISTOLOGIC TYPE
NO. OF
CASES
(n=50)
PERCENTAGE
(%)
IDC NOS 46 92
atypical medullary carcinoma 1 2
ILC 2 4
Medullary carcinoma 1 2
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CHART 3: DISTRIBUTION OF SAMPLES BASED ON HISTOLOGIC
TYPE
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TUMOR GRADE
Grading according to the Nottingham modification of Bloom and
Richardson system showed that 2% were grade I; 46% were grade II and 44%
were grade III.
TABLE 8: DISTRIBUTION OF CASES ACCORDING TO BLOOM
RICHARDSON GRADING SYSTEM
GRADE No. OF CASES (n=50) Percentage (%)
I
1 2
II
27 55
III
21 43
CHART 4: DISTRIBUTION OF CASES ACCORDING TO BLOOM
RICHARDSON GRADING SYSTEM
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ANGIOLYMPHATIC INVASION
In our study group, lymphovascular invasion on H&E stained sections
was observed in 32 cases (64%).
CHART 5: DISTRIBUTION OF CASESWITH LYMPHOVASCULAR
INVASION
PERINEURAL INVASION
Of the 50 cases in our study, 2 cases (4%) showed perineural invasion.
TABLE 9: DISTRIBUTION OF CASES WITH PERINEURAL INVASION
PERINEURAL
INVASION
NO. OF CASES
(N=50)
PERCENTAGE
(%)
Present 2 4%
Absent 48 96%
64%
36%
Present
Absent
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INSITU COMPONENT
Among the 50 cases studied, 8 cases (16%) showed DCIS component in
the rest of the parenchyma.
TABLE 10: DISTRIBUTION OF CASES WITH DCIS COMPONENT
DCIS COMPONENT
NO. OF CASES
(N=50)
PERCENTAGE
(%)
Present 8 16%
Absent 42 84%
CHART 6: DISTRIBUTION OF CASES WITH DCIS COMPONENT
16%
84%
Present
Absent
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TUMOR NECROSIS
Out of the 50 cases analyzed, 35 cases (70%) showed microscopic tumour
necrosis on histopathologic examination.
TABLE 11: DISTRIBUTION OF CASES WITH TUMOR NECROSIS
TUMOR NECROSIS
NO. OF CASES
(N=50)
PERCENTAGE
(%)
Present 35 70%
Absent 15 30%
CHART 7: DISTRIBUTION OF CASESWITH TUMOR NECROSIS
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LYMPH NODE STATUS
The thorough histological examination of the axillary lymph nodes
revealed that 38 % of cases had no lymph node while 20 % had 1-3 positive
lymph nodes and 30% had ≥ 4 positive lymph node metastasis. The lymph node
status in 12% of the cases could not be assessed.
CHART 8: DISTRIBUTION OF CASES ACCORDING TO LYMPH
NODE STATUS
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STROMAL REACTION
Out of the 50 cases studies, we observed stromal reaction in about 92% of
the cases, out of which 23 cases (46%) showed stromal fibrosis, 1 case (2%)
showed lymphocytic infiltration and 22 cases (44%) showed both fibrosis and
lymphocytic infiltration.
TABLE 12: DISTRIBUTION OF CASESWITH STROMAL REACTION
STROMAL REACTION
NO. OF CASES
(N=50)
PERCENTAGE
(%)
Lymphocytic infiltration 1 2%
Fibrosis 23 46%
Both 22 44%
None 4 8%
CHART 9: DISTRIBUTION OF CASES ACCORDING TO LYMPH
NODE STATUS
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IMMUNOHISTOCHEMICAL STUDY
CK 5/6 EXPRESSION
Among the 50 cases in the study population, CK 5/6 expression was
observed in only 10 cases (20%) and the remaining 40 cases (80%) showed
negative immunoreactivity for CK 5/6.
TABLE 13: DISTRIBUTION OF CASES WITH CK5/6 EXPRESSION
CK5/6 EXPRESSION
NO. OF CASES
(N=50)
PERCENTAGE
(%)
Positive 10 20%
Negative 40 80%
CHART10: PERCENTAGE OF CASES WITH
IMMUNOHISTOCHEMICAL EXPRESSION OF CK5/6 IN TNBC
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EGFR EXPRESSION
Out of the 50 cases, EGFR positive immunoreactivity was observed in 34
cases (68%) whereas 16 cases (32%) were negative for EGFR.
TABLE 14: DISTRIBUTION OF CASES WITH EGFR EXPRESSION
EGFR EXPRESSION
NO. OF CASES
(N=50)
PERCENTAGE
(%)
Positive 34 68%
Negative 16 32%
CHART 11: PERCENTAGE OF CASES WITH
IMMUNOHISTOCHEMICAL EXPRESSION OF EGFR IN TNBC
68%
32%
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Negative
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TABLE 15: IMMUNOHISTOCHEMICAL STATUS OF BASAL
MARKERS IN TNBC
IMMUNOHISTOCHEMICAL
PANEL
NO. OF CASES
(N=50)
PERCENTAGE
(%)
CK5/6 + / EGFR + 8 16
CK5/6 + / EGFR - 2 4
CK5/6 - / EGFR + 26 52
CK5/6 - / EGFR - 14 28
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CORRELATION OF TUMOR SIZE WITH LYMPH NODE STATUS
Among the 10 cases with tumour size < 2 cm, 7 cases did not exhibit any
lymph node metastasis, 1 case showed > 4 lymph node involvement and lymph
nodal status could not be assessed in 2 cases. Among the 32 cases with tumour
largest diameter 2-5 cm, 9 cases showed no nodal metastasis, 10 cases showed 1-
3 lymph node involvement and 11 cases showed > 4 nodes involvement. Out of
the 8 cases with largest tumour diameter > 5 cm, 3 showed no nodal
involvement, 3 showed > 4 nodes with metastasis and nodal status could not be
assessed in 2 cases.
TABLE 16: CORRELATION OF TUMOR SIZE WITH LYMPH NODE
STATUS
TUMOR SIZE
LYMPHNODE STATUS
P
VALUE
NONE 1-3 >4
COULD NOT
BE
ASSESSED
<2 cm 7 0 1 2
0.038*
2-5 cm 9 10 11 2
>5 cm 3 0 3 2
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The association between tumour size and lymph node status was assessed
using Chi-Square test. The P value of 0.038* was obtained, which revealed a
significant association between the both.
CHART 12: CORRELATION OF TUMOR SIZE WITH LYMPH NODE
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CORRELATION OF TUMOR SIZE WITH HISTOLOGIC GRADE
Among the 10 cases with largest tumour diameter < 2 cm, 4 cases were of
histologic grade II, 5 were of histologic grade III and one was atypical medullary
carcinoma. Among the 32 cases with tumour size 2-5 cm, 1 case was of grade I,
13 were of grade II, 15 were of grade III and 3 belonged to histologic types other
than IDC NOS.
TABLE 17: CORRELATION OF TUMOR SIZE WITH HISTOLOGIC
GRADE
TUMOR
SIZE
HISTOLOGIC GRADE P VALUE
I II III
<2 0 5 5
0.710
2-5 1 16 15
>5 0 6 2
75
CHART 13: CORRELATION OF TUMOR SIZE WITH HISTOLOGIC
GRADE
The association between tumour size and histologic grade was determined
using Chi-Square test. It revealed an insignificant P value of 0.694, proving that
there is no significant association between them.
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CORRELATION OF CK 5/6 EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS
We studied the association between CK 5/6 expression and
clinicopathologic parameters using Chi-Square test and did not observe any
positive association between them.
TABLE 18: CORRELATION OF CK 5/6 EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS- AGE AND TUMOR SIZE
PROGNOSTIC PARAMETERS CK5/6 P
VALUEPOSITIVE NEGATIVE
AGE
<40 years 2 6
0.87840-50 years 3 15
>50 years 5 19
TUMOR SIZE
<2 cm 3 7
0.5682-5 cm 5 27
>5 cm 2 6
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TABLE 19: CORRELATION OF CK 5/6 EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS- HISTOLOGIC TYPE,
GRADE AND TUMOR NECROSIS
PROGNOSTIC PARAMETERS CK5/6 P
VALUEPOSITIVE NEGATIVE
HISTOLOGIC
TYPE
IDC NOS 8 38
0.134Atypical
medullary 0 1
ILC 1 1
Medullary 1 0
HISTOLOGIC
GRADE
I 0 1
0.497
II 7 20
III 3 19
TUMOR
NECROSIS
Present 7 28
1.000
Absent 3 12
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TABLE 20: CORRELATION OF CK 5/6 EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS- STROMAL RESPONSE AND
LYMPHNODE STATUS
PROGNOSTIC PARAMETERS CK5/6 P
VALUEPOSITIVE NEGATIVE
STROMAL
RESPONSE
Fibrosis 2 16
0.391Lymphocytic
infiltration 6 13
Both 2 9
None 2
LYMPHNO
DE STATUS
None 6 13
0.2081-3 1 9
≥ 4 1 14
Could not be
assessed
2 4
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CORRELATION OF EGFR EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS
The association between EGFR expression and clinicopathologic
parameters was studied using Chi-Square test and we observed no significant
positive association between them.
TABLE 21: CORRELATION OF EGFR EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS- AGE AND TUMOR SIZE
PROGNOSTIC PARAMETERS EGFR
P
VALUE
POSITIVE NEGATIVE
AGE
<40 years 3 5
0.068
40-50 years 15 3
>50 years 16 8
TUMOR SIZE
<2 cm 9 1
0.174
2-5 cm 19 13
>5 cm 6 2
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TABLE 22: CORRELATION OF EGFR EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS- HISTOLOGIC TYPE,
GRADE AND TUMOR NECROSIS
PROGNOSTIC PARAMETERS EGFR P
VALUEPOSITIVE NEGATIVE
HISTOLOGIC
TYPE
IDC NOS 32 14 0.4
Atypical medullary 1 0
ILC 1 1
Medullary 0 1
HISTOLOGIC
GRADE
I 0 1 0.305
II 18 9
III 16 6
TUMOR
NECROSIS
Present 9 6
0.907
Absent 13 6
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TABLE 23: CORRELATION OF EGFR EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS- STROMAL RESPONSE AND
LYMPHNODE STATUS
PROGNOSTIC
PARAMETERS
EGFR
P VALUE
POSITIVE NEGATIVE
STROMAL
RESPONSE
Fibrosis 12 6 0.735
Lymphocytic
infiltration
12 7
Both 8 3
None 2
LYMPH
NODE
STATUS
None 12 7 0.343
1-3 5 5
≥ 4 12 3
Could not be
assessed
5 1
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DISCUSSION
Breast cancer is a heterogeneous disease encompassing a variety of
distinct clinical, morphological and molecular features exhibiting a range of
clinical characteristics and therapeutic implications8,126.Triple-negative breast
cancer is defined by the lack of expression of hormone receptors and Her2
overexpression. They are distinct because of their aggressive clinical behaviour
and characteristic clinicopathologic prognostic factors104.
Nielsen et al. studied the immunohistochemical profile for triple-negative
tumours using an immunohistochemical panel consisting of basal cytokeratins
and evaluated the prognostic significance of these markers on the tumors41.
Cheang et al. studied the use of the immunohistochemical panel comprising of
five biomarkers ER, PR, Her2, CK 5/6 and EGFR and found that it is a highly
helpful tool as a immunohistochemical surrogate for the detection of basal-like
breast cancer and hence their therapeutic strategy for treatment98.
In the present study, the triple-negative breast cancer phenotype was
correlated with the clinical and histopathologic parameters such as age, tumour
size, histologic type, histologic grade, lymphovascular invasion, lymph nodal
status, associated DCIS component, stromal response and the
immunohistochemical expression of basal markers namely CK5/6 and EGFR.
Although the predominant age group affected in this current study was <
50 years (52%) followed by patients aged >50 years (48%) with a mean age of
50.4 years. In a study by Rao et al. the mean age was found to be 46.8 years127.
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Thike et al. observed a mean age of 53 years in their study126. Hashmi et al.
Observed the mean age to be 48.4 years128. Tan et al. observed that Triple
negative breast cancers are common in patients aged >40 years129. In the present
study, we did not observe any significant correlation between the expression of
CK 5/6 and EGFR and age of the patients.
In the present study, we observed an increased percentage of triple
negative breast cancer to be of infiltrating ductal carcinoma IDC, NOS type
(92%) followed by other histologic types such as invasive lobular carcinoma and
medullary carcinoma. This finding suggests that TNBC can present in various
histomorphologic types126. Rao et al. Thike et al. and Hashmi et al. also observed
the similar findings in their study126–128. However, no significant correlation was
found between the histologic type and expression of CK 5/6 and EGFR.
In our study, we observed the histologic grades of TNBC to be
predominantly grades II and III, 46% and 44% respectively. In a study by Thike
et al, they observed an incidence of  77% of grade III histology TNBC126.
Hashmi et al also observed an increased frequency of grade III tumours of about
63.4%128. Rao et al study shows grade III tumours with 76% occurrence127.
In the present study, the mean tumour size was 4.01 cm. A majority of
tumours 64 % were in the range of 2-5 cm size along largest diameter. Kreike et
al studied 97 cases of triple negative breast cancers and found 65% of tumours to
be >2 cm in largest dimension130. Although Thike et al126 found 70% cases to be
> 2cm in size and observed a significant correlation between larger tumours and
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CK 5/6 expression, our study did not show any significant correlation between
CK 5/6 and EGFR expression and tumour size as observed by Rao et al and Tan
et al127,129.
In our study, we observed tumour necrosis in 70% of the cases studied, in
the form of both focal and comedonecrosis. This finding is concordant with the
observation by Thike et al and Hashmi et al who observed tumour necrosis in
98% and 96.4% of the cases respectively126,128. No significant correlation was
observed between basal markers and tumour necrosis which is discordant with
the observation by Rao et al who found a significant association between
them127.
In the current study, we observed DCIS component around the tumour in
about 16% of the cases. Kreike et al also observed DCIS component in 18% of
the TNBC cases130. Lymphovascular invasion was observed less frequently in
various series with incidence ranging from 20-29%126–128 only whereas in our
current study, we observed lymphovascular invasion in 64% of cases, which is
slightly on the higher side. Lymphocytic infiltration was seen in 46% of the cases
and did not show statistically significant correlation with CK 5/6 and EGFR.
Lymph node metastasis in triple negative breast cancer has been studied
and the results of various series show varied results. The results of some series
showed high prevalence rates of node positive TNBC48,95. In our study, the
lymph node metastases were observed in 50% of the cases.
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We carried out a correlation test between tumour size and lymph node
status and found a positive correlation with significant P value of 0.038. This
finding was concordant with the observation by Thike et al who found that
increasing incidence of nodal metastases with increasing tumour sizes126 and
discordant with the findings by Dent et al104, who observed decreasing incidence
of axillary lymph node involvement with increasing tumour sizes.
In the present study, we studied the expressions of CK5/6 and EGFR
using immunohistochemistry. We observed that a large proportion of the triple
negative breast cancers expressed at least one of the two markers- CK5/6 and/ or
EGFR (72%). These results were in concordance with the results of Rao et al and
Choccalingam et al who found 74% and 67.7% cases respectively with
expression of CK 5/6 and/ or EGFR125,127.
The basal cytokeratin CK 5/6 was expressed by less than a quarter of the
total number of cases (20%), which is less when compared to other previous
studies by Nielsen et al and Livasy et al41,117. The expression of EGFR was
observed in 68% of the cases, which is concordant with the previous studies
117,125,127
. These observations entail an overlap between ‘triple negativity’ and
‘basalness’. Similar results were obtained in studies by Rakha et al and
Choccalingam et al48,125. Foulkes et al suggest the term “core basal” phenotype to
specify the tumours which have triple negativity for ER, PR and Her2 and
express at least one of the basal markers CK 5/6 and/ or EGFR. These have a
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worse clinical outcome than the tumours which lack expression of all the five
markers108.
The important histologic features of tumours with basal-like phenotype
like high tumour grade, lymphocytic infiltration, scant tumour stroma, lymph
node metastases, tumour necrosis in the form of geographic necrosis and comedo
necrosis, high nuclear grade, increased mitotic rate, frequent apoptosis were also
noted in the current study10.
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SUMMARY
This study was conducted in the Department of Pathology, Tirunelveli
Medical College in 50 cases of triple-negative primary invasive breast
carcinoma. The clinical and histopathologic parameters such as age, tumour size,
histologic type, histologic grade, tumour necrosis, lymph node metastases,
stromal reaction, lymphovascular invasion, DCIS component were assessed in
haematoxylin and eosin stained sections of the tumour tissue, followed by
immunohistochemical analysis using CK 5/6 and EGFR was performed.
Among the 50 cases, 46 cases (92%) were infiltrating ductal carcinoma
NOS type, 2 cases (4%) were invasive lobular carcinoma, 1 case (2%) was
medullary carcinoma and 1 case (2%) was atypical medullary carcinoma.
Among the 50 cases, 1case (2%) was of grade I histology, 27 cases (54%) were
under grade II, and 21 cases (42%) were grade III tumours.
Among the 50 cases, 32 cases (64%) had tumour size of 2-5 cm along the
largest dimension, 32 cases (64%) showed lymphovascular invasion, 8 cases
(16%) had associated in situ component around the tumour, 35 cases (70%) had
areas of tumour necrosis, 23 cases (46%) had lymphocytic infiltrates and 23
cases (46%) had stromal fibrosis and 25 cases (50%) had lymph node metastases
at the time of diagnosis.
Among the 50 cases, 36 cases (72%) expressed at least one of the basal
markers CK 5/6 and/ or EGFR. 10 cases (20%) expressed CK 5/6 and 34 cases
(68%) expressed EGFR. No statistically significant correlation was noted
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between the expression of basal markers CK 5/6 and EGFR and the
clinicopathologic prognostic parameters. A strong correlation was found between
the tumour size and axillary lymph node metastases with a statistically
significant P value of 0.038.
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CONCLUSION
Triple-negative breast cancer subtype is a heterogeneous entity which
comprises of tumours with distinct clinical and morphologic characteristics.
Among these, the basal-like phenotype, as identified by the expression of basal
markers CK 5/6 and EGFR, exhibits an aggressive clinical behaviour with poor
therapeutic outcomes. The triple-negativity of tumours should not be used as a
marker for basal-like tumours. With the use of the basal markers CK 5/6 and
EGFR, a clinically aggressive phenotype with poor clinical outcome, the basal-
like phenotype can be identified among the triple-negative breast cancer. A large
majority of triple negative breast cancers express EGFR, which can be used as a
potential target for treatment.
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FIGURE 3(A) : INVASIVE DUCTAL CARCINOMA SHOWING
TRABECULAR AND NESTED PATTERN OF GROWTH
FIGURE 3 (B): COMEDO NECROSIS IN A CASE OF CARCINOMA OF
BREAST
FIGURE 3 (C): HIGH NUCLEAR GRADE AND INCREASED MITOTIC
RATE IN A CASE OF BREAST CARCINOMA (HE, x40)
FIGURE 3 (D): INVASION OF MEDIUM SIZED BLOOD VESSEL IN A CASE
OF IDC NOS TYPE
FIGURE 3 (E): PERINEURAL INVASION AT THE INVASIVE FRONT OF
TUMOR IN A CASE OF DUCTAL CARCINOMA OF BREAST
FIGURE 3 (F): INVASIVE DUCTAL CARCINOMA WITH DCIS
COMPONENT
FIGURE 4 (A): IMMUNOHISTOCHEMICAL STAINING SHOWING
INTENSE POSITIVITY FOR CYTOKERATIN 5/6
FIGURE 4 (B): IMMUNOHISTOCHEMICAL STAINING SHOWING
INTENSE POSITIVITY FOR EGFR
FIGURE 4 (C): IMMUNOHISTOCHEMISTRY SHOWING NEGATIVE
STAINING FOR CYTOKERATIN 5/6 WITH POSITIVE STAINING OF
INTERNAL CONTROL
ANNEXURE- I
WHO CLASSIFICATION OF TUMORS OF BREAST
Epithelial tumours
1. Invasive ductal carcinoma, not otherwise specified
a. Pleomorphic carcinoma
b. Carcinoma with melanotic features
c. Carcinoma with choriocarcinomatous features
d. Carcinoma with osteoclast like giant cells
2. Invasive lobular carcinoma
a. Classic lobular carcinoma
b. Solid lobular carcinoma
c. Alveolar lobular carcinoma
d. Pleomorphic lobular carcinoma
e. Tubulolobular lobular carcinoma
f. Mixed lobular carcinoma
3. Tubular carcinoma
4. Cribriform carcinoma
5. Carcinoma with medullary features
a. Medullary carcinoma
b. Atypical medullary carcinoma
c. Invasive carcinoma NST with medullary features
6. Metaplastic carcinoma of no special type
a. Low-grade adenosquamous carcinoma
b. Fibromatosis-like metaplastic carcinoma
c. Squamous cell carcinoma
d. Spindle cell carcinoma
e. Metaplastic carcinoma with mesenchymal differentiation
i. Chondroid differentiation
ii. Osseous differentiation
iii. Other types of mesenchymal differentiation
f. Mixed metaplastic carcinoma
g. Myoepithelial carcinoma
7. Mucinous carcinoma
8. Carcinoma with signet-ring-cell differentiation
9. Carcinoma with neuroendocrine features
10. Carcinoma with apocrine differentiation
11. Invasive papillary carcinoma
12. Invasive micropapillary carcinoma
13. Adenoid cystic carcinoma
14. Mucoepidermoid carcinoma
15. Salivary gland/skin adnexal type tumours
16. Polymorphous carcinoma
17. Inflammatory carcinoma
18. Bilateral breast carcinoma and non-synchronous breast carcinoma
19. Exceptionally rare types and variants
Secretory carcinoma
Oncocytic carcinoma
Sebaceous carcinoma
Lipid-rich carcinoma
Glycogen-rich clear cell carcinoma
Acinic cell carcinoma
Lobular neoplasia
Intraductal proliferative lesions
 Usual ductal hyperplasia
 Columnar cell lesions
 Atypical ductal hyperplasia
 Ductal carcinoma in situ
Intraductal papillary lesions
 Intraductal papilloma
 Intraductal papillary carcinoma
 Encapsulated papillary carcinoma
 Solid papillary carcinoma
Benign epithelial proliferations
1. Adenosis, sclerosing adenosis and
apocrine adenosis
2. Microglandular adenosis,
atypical microglandular adenosis and
microglandular adenosis with carcinoma
3. Radial scar and complex sclerosing lesion
4. Tubular adenoma
5. Lactating adenoma
6. Apocrine adenoma
7. Ductal adenoma
8. Pleomorphic adenoma
Myoepithelial and epithelial–myoepithelial lesions
 Myoepithelial and epithelial–myoepithelial lesions
 Adenomyoepithelioma and adenomyoepithelioma
with carcinoma
Mesenchymal tumours
1. Nodular fasciitis
2. Benign vascular lesions
3. Pseudoangiomatous stromal hyperplasia
4. Myofibroblastoma
5. Desmoid-type fibromatosis
6. Inflammatory myofibroblastic tumour
7. Lipoma
8. Granular cell tumour and benign peripheral nerve-sheath tumour
9. Angiosarcoma
10. Liposarcoma
11. Rhabdomyosarcoma
12. Osteosarcoma
13. Leiomyoma and leiomyosarcoma
Fibroepithelial tumours
 Fibroadenoma
 Phyllodes tumour
 Hamartoma
Tumours of the nipple
 Nipple adenoma
 Syringomatous tumour
 Paget disease
Lymphoid and haematopoietic tumours
 Diffuse large B-cell lymphoma
 Burkitt lymphoma
 T-cell lymphoma
 Extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue
 Follicular lymphoma
Metastases to the breast
Tumours of the male breast
 Gynaecomastia
 Carcinoma of the male breast
ANNEXURE 2
PROCESSING FOR IMMUNOHISTOCHEMISTRY
1. 4-5µm thick sections are cut using microtome from the selected paraffin
blocks.
2. The sections are taken on poly L-lysine coated adhesive slides. The slides were
incubated at 60-70º C for one hour.
3. The slides are subjected to 2 changes of xylene 5 minutes each.
4. They are then transferred to absolute alcohol for 5 minutes followed by
by 90% and 70% alcohol for 5 minutes to rehydrate the tissue sections.
5. The tissue sections are then placed in running tap water for 5 minutes and
washed in distilled water
6. Antigen retrieval is performed using microwave oven in specific buffer
solution - TRIS EDTA buffer
7. Then the sections are cooled to room temperature and the slides are
washed with distilled water
8. Endogenous peroxidase activity is prevented by incubating the tissue
sections with adequate use of peroxidase blocking solution in a humid chamber
for 5 minutes. The sections are then washed in TRIS wash buffer.
9. The primary antibody (CK 5/6 and EGFR) is then added over the tissue
sections and incubated for 30 minutes.
10. The tissue sections are then washed in TRIS wash buffer.
11. A primary amplifier is added for 15 minutes to enhance the application of
primary antibody which is then followed by washing in TRIS wash buffer
12. The secondary antibody is added and incubated for 12 minutes and then
washed with TRIS wash buffer
13. The working solution of DAB chromogen (1ml DAB buffer +1 drop DAB
chromogen) is then added over the tissue and incubated for 2-5 minutes and
then washed with 2 changes of distilled water.
14. Counterstaining of nuclei was done with Harris’ haematoxylin for 30 seconds
and washed in running tap water.
15. Dehydration is done by 2 changes each in increasing grades of alcohol.
16. Mounting is done by DPX mountant and observed under microscope.
BUFFER PREPARATIONS
1. TRIS – EDTA BUFFER: pH- 9.0
Tris - 6.05 gm
EDTA - 0.744 gm
Distilled water - 1000 ml
2. TRIS WASH BUFFER
Tris - 0.605 gm
Sodium chloride - 8 gm
1 N HCl - 4ml
Distilled water - 1000 ml
PRECAUTIONS
1. The glassware used should be dry and clean.
2. All the buffer solutions used should be prepared fresh and the pH should be
adjusted accordingly
3. The staining procedures are never allowed to dry so they are performed
under a humidified chamber.
4. The DAB chromogen should be handled and disposed carefully as it is a
carcinogen.
5. The primary and secondary antibody, DAB chromogen, peroxidase block, and
amplifier, everything should be stored at 4-6ºC.
ANNEXURE- III
ALLRED SCORING GUIDELINES FOR ER AND PR
Proportion score
Proportion score is done by calculating the proportion of tumour cells with stained
nuclei.
0 = no nuclear staining
1 = <1% nuclear staining
2 = 1%-10% nuclear staining,
3 = 11%-33% nuclear staining
4 = 34%-66% nuclear staining
5 = 67%-100% nuclear staining
Intensity of staining
0 = no staining
1 = weak staining
2 = moderate staining
3 = strong staining
Total score =proportion score + intensity score (0 to 8)
Interpretation:
0,2 – Negative
≥ 3 - Positive
GRADING OF THE IMMUNOHISTOCHEMICAL STAINING FOR HER 2
OVEREXPRESSION
SCORE STAINING PATTERN HER 2
OVEREXPRESSION
ASSESSMENT
0 No staining at all or very slight partial
membrane staining in less than 10% of
tumour cells.
Negative
1+ Faint barely perceptible membrane
staining in more than    10%     of tumour
cells. Cells stained in only part of the
membrane.
Negative
2+ Weak to moderate complete membrane
staining observed in more than 10% of
tumour cells.
Weakly Positive
3+ Strong complete membrane staining in
more  than 30% of tumour cells
Strongly Positive
SCORING FOR CYTOKERATIN (CK5/6)
Cytokeratin 5/6 was scored as positive if any faint or strong cytoplasmic and/or
membranous immunostaining was observed in the neoplastic tumour cells.
SCORING FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
EGFR was scored as positive if more than 1% of the tumour cells showed
membrane immunoreactivity of any intensity.
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1 2207/15 55 attained MRM 3.5 absent 12 2 0.3 IDC NOS III present absent absent present fibrosis free involved involved 7 negative negative -/-
2 472/15 55 attained completion mastectomy 7 present 1 2 - IDC NOS II present absent absent present lymphocytic infiltration free free free free negative negative -/-
3 1358/15 40 - simple mastectomy with axillaryclearance 3 absent 1 0.3 -
medullary
carcinoma - absent absent absent present fibrosis free free free free positive negative +/-
4 2381/15 56 attained MRM 2 absent 2 0.5 0.4 IDC NOS II absent absent absent present lymphocytic infiltration free free free free negative negative -/-
5 1547/15 40 attained MRM 5 present 22 2 1 IDC NOS II present absent absent present lymphocytic infiltration free free free free negative negative -/-
6 1218/15 50 attained MRM 5 absent 8 1 0.2 IDC NOS III present absent absent present fibrosis free free free 3 negative negative -/-
7 1717/15 52 attained MRM 4 absent 5 3 0.5 IDC NOS III present absent absent absent fibrosis & lymphocytic free free free free negative positive -/+
8 2683/15 36 - MRM 11 absent 12 1.5 0.3 IDC NOS II absent absent absent present lymphocytic infiltration free free free free negative negative -/-
9 3320/15 47 - MRM 2 absent - - - IDC NOS II absent absent absent absent fibrosis free free free - positive positive +/+
10 3520/15 60 attained MRM 9 absent 5 1 0.3 IDC NOS II present absent absent absent fibrosis free free free 5 positive positive +/+
11 2840/15 56 attained MRM 2.5 absent 11 2 0.5 IDC NOS III present absent absent absent fibrosis & lymphocytic free free free 9 negative positive -/+
12 2598/15 47 - mastectomy with axillaryclearance 8 absent - - - IDC NOS II absent absent present present fibrosis involved free free - negative positive -/+
13 1850/15 44 - MRM 3.5 present 19 4 0.3 IDC NOS III present absent absent present fibrosis & lymphocytic free free free 12 negative positive -/+
14 3846/15 48 - MRM 2 absent - - - IDC NOS II present absent present absent lymphocytic infiltration free free free - negative positive -/+
15 3628/15 51 attained MRM 4 absent 10 1.5 0.5 IDC NOS II absent absent absent present fibrosis & lymphocytic free free free free positive positive +/+
16 939/15 55 - simple mastectomy with axillaryclearance 5 present 3 2 0.5 IDC NOS II present absent absent present fibrosis & lymphocytic free free free 3 negative negative -/-
17 3209/16 56 attained MRM 7 absent 9 2 0.8 IDC NOS II absent absent present present fibrosis free free free free positive positive +/+
18 2027/16 44 - MRM 2 present 7 2.5 1 IDC NOS III absent absent absent present lymphocytic infiltration free free free free positive positive +/+
19 2006/15 33 - MRM 3 absent 8 1 0.3 ILC - present absent absent present fibrosis & lymphocytic free free free - positive negative +/-
20 2980/15 57 attained bilateral MRM 9 present - - - IDC NOS II present absent absent present lymphocytic infiltration free involved free - negative positive -/+
20 2980/15 57 attained bilateral MRM 4 present 8 2 0.3 IDC NOS II present absent present present lymphocytic infiltration free involved free 8 negative positive -/+
21 3607/15 42 - simple mastectomy with axillaryclearance 6 absent 14 2 0.5 IDC NOS III present absent absent present - free free free 14 negative positive -/+
22 3358/15 65 attained simple mastectomy with axillaryclearance 4 absent 4 2 0.5 IDC NOS II present present absent absent fibrosis free free free 2 negative positive -/+
23 1261/16 22 - MRM 1.5 absent 5 1 0.3 IDC NOS III absent absent absent present lymphocytic infiltration free free free free negative positive -/+
24 763/16 42 - MRM 4.5 absent 4 1 0.2 IDC NOS III present absent absent present fibrosis & lymphocytic free free involved 4 negative positive -/+
25 1260/16 50 attained MRM 3.5 absent 8 1 0.5 IDC NOS I absent absent absent absent fibrosis free free free free negative negative -/-
26 1362/16 50 - MRM 1 absent 8 1 0.3 IDC NOS III present absent present absent fibrosis free free free free positive positive +/+
27 775/16 56 attained MRM 4 absent 4 1.5 0.2 IDC NOS II present absent present present lymphocytic infiltration free free free 2 negative positive -/+
29 208/16 38 - MRM 4 absent 7 1.5 0.5 IDC NOS III present absent present present fibrosis free free free free negative positive -/+
30 671/16 60 attained MRM 4 absent 4 1.5 0.2 IDC NOS III absent absent absent present fibrosis free free free 1 positive positive +/+
31 762/16 63 attained MRM 1.5 present 10 1 0.2 IDC NOS III absent absent absent present fibrosis free involved involved free negative positive -/+
32 210/16 46 - MRM 3 absent IDC NOS III present absent absent present fibrosis free free free - negative positive -/+
33 3375/16 70 attained simple mastectomy with axillaryclearance 3 absent 11 1.5 0.2 IDC NOS III present absent absent absent fibrosis &  lymphocytic free free free 4 negative negative -/-
34 3615/16 45 - MRM 4 absent 12 2.5 0.5 IDC NOS II present absent absent absent lymphocytic infiltration free free free 4 negative negative -/-
35 1526/16 65 attained MRM 1 present 19 3.5 0.5 IDC NOS II absent absent absent present lymphocytic infiltration free free free free negative positive -/+
36 3605/15 53 - MRM 3.5 present 7 2.5 0.5 IDC NOS III present absent absent present fibrosis free free free 2 negative negative -/-
37 1599/16 35 - MRM 2.5 absent 14 1.5 0.5 IDC NOS III present absent present present - free free free 1 negative positive -/+
38 1620/16 47 - MRM 4 absent 21 3 0.8 IDC NOS III present absent absent present fibrosis free free free 8 negative positive -/+
39 4104/16 47 - MRM 2 present 9 2 0.5 IDC NOS III absent absent absent absent fibrosis & lymphocytic involved free free 5 negative positive -/+
40 1949/16 49 - MRM 4 present 16 1.5 0.5 IDC NOS II present present absent absent lymphocytic infiltration free free free 5 negative positive -/+
41 1598/16 50 - MRM 3 absent 5 1.5 0.5 ILC - absent absent absent present lymphocytic infiltration free free free free negative positive -/+
42 4007/16 48 - MRM
2 absent 2 1 0.5
atypical
medullary
carcinoma - present absent absent present fibrosis & lymphocytic free free free free negative positive -/+
43 3653/16 52 attained MRM 3.5 present 12 2 0.5 IDC NOS III absent absent absent absent fibrosis involved free free 2 negative negative -/-
44 4115/16 51 attained MRM 4 present 12 2.5 0.5 IDC NOS II absent absent absent absent fibrosis free free free free negative negative -/-
45 1999/16 38 - MRM 4 absent 13 4.5 0.5 IDC NOS III present absent absent absent lymphocytic infiltration free free free 1 negative negative -/-
46 1146/16 52 attained MRM 2.5 present 5 0.5 0.3 IDC NOS II present absent absent present lymphocytic infiltration free free free free positive positive +/+
47 41/16 48 - MRM 3 present 10 2 0.5 IDC NOS II present absent absent present lymphocytic infiltration free free free 7 negative positive -/+
48 4747/16 62 attained MRM 5 present 14 2.5 0.8 IDC NOS II present absent absent present fibrosis free free free 8 negative positive -/+
49 8002/16 70 attained MRM 7 present 16 3 0.5 IDC NOS III present absent absent present fibrosis & lymphocytic free free involved 12 negative positive -/+
50 3833/14 65 attained MRM 4 present 6 2 0.5 IDC NOS II absent absent absent present lymphocytic infiltration free free free 1 negative positive -/+
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US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
13 1850/15 44 - MRM 3.5
pre
sen
t
19 4 0.3
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
fre
e 12
ne
gat
ive
po
siti
ve
14 3846/15 48 - MRM 2
ab
sen
t
- - -
IDC
 NO
S
II
pre
sen
t
ab
sen
t
pre
sen
t
ab
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e -
ne
gat
ive
po
siti
ve
15 3628/15 51
att
ain
ed MRM 4
ab
sen
t
10 1.5 0.5
IDC
 NO
S
II
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
fre
e
fre
e
po
siti
ve
po
siti
ve
16 939/15 55 -
simple
mastectomy
with axillary
clearance
5
pre
sen
t
3 2 0.5
IDC
 NO
S
II
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
fre
e 3
ne
gat
ive
ne
gat
ive
17 3209/16 56
att
ain
ed MRM 7
ab
sen
t
9 2 0.8
IDC
 NO
S
II
ab
sen
t
ab
sen
t
pre
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e
fre
e
po
siti
ve
po
siti
ve
S.
NO PATH NO
AG
E (
Yrs
)
ME
NO
PA
US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
18 2027/16 44 - MRM 2
pre
sen
t
7 2.5 1
IDC
 NO
S
III
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e
fre
e
po
siti
ve
po
siti
ve
19 2006/15 33 - MRM 3
ab
sen
t
8 1 0.3 ILC - pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
fre
e -
po
siti
ve
ne
gat
ive
20 2980/15 57
att
ain
ed bilateral MRM 9
pre
sen
t
- - -
IDC
 NO
S
II
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
inv
olv
ed
fre
e -
ne
gat
ive
po
siti
ve
20 2980/15 57
att
ain
ed bilateral MRM 4
pre
sen
t
8 2 0.3
IDC
 NO
S
II
pre
sen
t
ab
sen
t
pre
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
inv
olv
ed
fre
e 8
ne
gat
ive
po
siti
ve
S.
NO PATH NO
AG
E (
Yrs
)
ME
NO
PA
US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
21 3607/15 42 -
simple
mastectomy
with axillary
clearance
6
ab
sen
t
14 2 0.5
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
- fre
e
fre
e
fre
e 14
ne
gat
ive
po
siti
ve
22 3358/15 65
att
ain
ed
simple
mastectomy
with axillary
clearance
4
ab
sen
t
4 2 0.5
IDC
 NO
S
II
pre
sen
t
pre
sen
t
ab
sen
t
ab
sen
t
fib
ros
is
fre
e
fre
e
fre
e 2
ne
gat
ive
po
siti
ve
23 1261/16 22 - MRM 1.5
ab
sen
t
5 1 0.3
IDC
 NO
S
III
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
po
siti
ve
24 763/16 42 - MRM 4.5
ab
sen
t
4 1 0.2
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
inv
olv
ed 4
ne
gat
ive
po
siti
ve
25 1260/16 50
att
ain
ed MRM 3.5
ab
sen
t
8 1 0.5
IDC
 NO
S
I
ab
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
fib
ros
is
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
ne
gat
ive
26 1362/16 50 - MRM 1
ab
sen
t
8 1 0.3
IDC
 NO
S
III
pre
sen
t
ab
sen
t
pre
sen
t
ab
sen
t
fib
ros
is
fre
e
fre
e
fre
e
fre
e
po
siti
ve
po
siti
ve
S.
NO PATH NO
AG
E (
Yrs
)
ME
NO
PA
US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
27 775/16 56
att
ain
ed MRM 4
ab
sen
t
4 1.5 0.2
IDC
 NO
S
II
pre
sen
t
ab
sen
t
pre
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e 2
ne
gat
ive
po
siti
ve
29 208/16 38 - MRM 4
ab
sen
t
7 1.5 0.5
IDC
 NO
S
III
pre
sen
t
ab
sen
t
pre
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
po
siti
ve
30 671/16 60
att
ain
ed MRM 4
ab
sen
t
4 1.5 0.2
IDC
 NO
S
III
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e 1
po
siti
ve
po
siti
ve
31 762/16 63
att
ain
ed MRM 1.5
pre
sen
t
10 1 0.2
IDC
 NO
S
III
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is
fre
e
inv
olv
ed
inv
olv
ed
fre
e
ne
gat
ive
po
siti
ve
32 210/16 46 - MRM 3
ab
sen
t
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e -
ne
gat
ive
po
siti
ve
33 3375/16 70
att
ain
ed
simple
mastectomy
with axillary
clearance
3
ab
sen
t
11 1.5 0.2
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
fre
e 4
ne
gat
ive
ne
gat
ive
S.
NO PATH NO
AG
E (
Yrs
)
ME
NO
PA
US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
34 3615/16 45 - MRM 4
ab
sen
t
12 2.5 0.5
IDC
 NO
S
II
pre
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e 4
ne
gat
ive
ne
gat
ive
35 1526/16 65
att
ain
ed MRM 1
pre
sen
t
19 3.5 0.5
IDC
 NO
S
II
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
po
siti
ve
36 3605/15 53 - MRM 3.5
pre
sen
t
7 2.5 0.5
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e 2
ne
gat
ive
ne
gat
ive
37 1599/16 35 - MRM 2.5
ab
sen
t
14 1.5 0.5
IDC
 NO
S
III
pre
sen
t
ab
sen
t
pre
sen
t
pre
sen
t
- fre
e
fre
e
fre
e 1
ne
gat
ive
po
siti
ve
38 1620/16 47 - MRM 4
ab
sen
t
21 3 0.8
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e 8
ne
gat
ive
po
siti
ve
39 4104/16 47 - MRM 2
pre
sen
t
9 2 0.5
IDC
 NO
S
III
ab
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
fib
ros
is &
lym
ph
ocy
tic
inv
olv
ed
fre
e
fre
e 5
ne
gat
ive
po
siti
ve
S.
NO PATH NO
AG
E (
Yrs
)
ME
NO
PA
US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
40 1949/16 49 - MRM 4
pre
sen
t
16 1.5 0.5
IDC
 NO
S
II
pre
sen
t
pre
sen
t
ab
sen
t
ab
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e 5
ne
gat
ive
po
siti
ve
41 1598/16 50 - MRM 3
ab
sen
t
5 1.5 0.5 ILC - ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
po
siti
ve
42 4007/16 48 - MRM 2
ab
sen
t
2 1 0.5
aty
pic
al m
ed
ull
ary
car
cin
om
a
-
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
po
siti
ve
43 3653/16 52
att
ain
ed MRM 3.5
pre
sen
t
12 2 0.5
IDC
 NO
S
III
ab
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
fib
ros
is
inv
olv
ed
fre
e
fre
e 2
ne
gat
ive
ne
gat
ive
44 4115/16 51
att
ain
ed MRM 4
pre
sen
t
12 2.5 0.5
IDC
 NO
S
II
ab
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
fib
ros
is
fre
e
fre
e
fre
e
fre
e
ne
gat
ive
ne
gat
ive
S.
NO PATH NO
AG
E (
Yrs
)
ME
NO
PA
US
E
TYPE OF
SURGERY
TU
MO
R S
IZE
 (C
M)
NE
CR
OS
IS
NO
. O
F N
OD
ES
LA
RG
EST
 NO
DE
  (C
M)
SM
AL
LES
T N
OD
E (
CM
)
HIS
TO
LO
GIC
AL
 TY
PE
GR
AD
E
LV
 IN
VA
SIO
N
PE
RIN
EU
RA
L IN
VA
SIO
N
INS
ITU
 CO
MP
ON
EN
T
NE
CR
OS
IS
STR
OM
AL
 RE
AC
TIO
N
MA
RG
INS
SK
IN
NIP
PLE
 & 
AR
EO
LA
INV
OL
VE
D L
YM
PH
NO
DE
S
CK
5/6 EG
FR
45 1999/16 38 - MRM 4
ab
sen
t
13 4.5 0.5
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
ab
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e 1
ne
gat
ive
ne
gat
ive
46 1146/16 52
att
ain
ed MRM 2.5
pre
sen
t
5 0.5 0.3
IDC
 NO
S
II
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e
fre
e
po
siti
ve
po
siti
ve
47 41/16 48 - MRM 3
pre
sen
t
10 2 0.5
IDC
 NO
S
II
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e 7
ne
gat
ive
po
siti
ve
48 4747/16 62
att
ain
ed MRM 5
pre
sen
t
14 2.5 0.8
IDC
 NO
S
II
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is
fre
e
fre
e
fre
e 8
ne
gat
ive
po
siti
ve
49 8002/16 70
att
ain
ed MRM 7
pre
sen
t
16 3 0.5
IDC
 NO
S
III
pre
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
fib
ros
is &
lym
ph
ocy
tic
fre
e
fre
e
inv
olv
ed 12
ne
gat
ive
po
siti
ve
50 3833/14 65
att
ain
ed MRM 4
pre
sen
t
6 2 0.5
IDC
 NO
S
II
ab
sen
t
ab
sen
t
ab
sen
t
pre
sen
t
lym
ph
ocy
tic
inf
iltr
ati
on
fre
e
fre
e
fre
e 1
ne
gat
ive
po
siti
ve
CK
5/6
/EG
FR
-/-
-/-
+/-
-/-
-/-
-/-
CK
5/6
/EG
FR
-/+
-/-
+/+
+/+
-/+
-/+
CK
5/6
/EG
FR
-/+
-/+
+/+
-/-
+/+
CK
5/6
/EG
FR
+/+
+/-
-/+
-/+
CK
5/6
/EG
FR
-/+
-/+
-/+
-/+
-/-
+/+
CK
5/6
/EG
FR
-/+
-/+
+/+
-/+
-/+
-/-
CK
5/6
/EG
FR
-/-
-/+
-/-
-/+
-/+
-/+
CK
5/6
/EG
FR
-/+
-/+
-/+
-/-
-/-
CK
5/6
/EG
FR
-/-
+/+
-/+
-/+
-/+
-/+
